# 1 The mutagenic forces shaping the genomic landscape of lung cancer in never

## 2 smokers

- 3
- 4 Marcos Díaz-Gay<sup>1-3,^</sup>, Tongwu Zhang<sup>4,^</sup>, Phuc H. Hoang<sup>4</sup>, Azhar Khandekar<sup>1-4</sup>, Wei Zhao<sup>4</sup>,
- 5 Christopher D. Steele<sup>1-3</sup>, Burçak Otlu<sup>1-3,5</sup>, Shuvro P. Nandi<sup>1-3</sup>, Raviteja Vangara<sup>1-3</sup>, Erik N.
- 6 Bergstrom<sup>1-3</sup>, Mariya Kazachkova<sup>1-3</sup>, Oriol Pich<sup>6</sup>, Charles Swanton<sup>6,7</sup>, Chao Agnes Hsiung<sup>8</sup>, I-
- 7 Shou Chang<sup>9</sup>, Maria Pik Wong<sup>10</sup>, Kin Chung Leung<sup>11</sup>, Jian Sang<sup>4</sup>, John McElderry<sup>4</sup>, Lixing
- 8 Yang<sup>12</sup>, Martin A Nowak<sup>13</sup>, Jianxin Shi<sup>4</sup>, Nathaniel Rothman<sup>4</sup>, David C. Wedge<sup>14,15</sup>, Robert
- 9 Homer<sup>16</sup>, Soo-Ryum Yang<sup>17</sup>, Qing Lan<sup>4</sup>, Bin Zhu<sup>4</sup>, Stephen J. Chanock<sup>4</sup>, Ludmil B.
- 10 Alexandrov<sup>1-3,18,\*</sup>, Maria Teresa Landi<sup>4,\*</sup>
- 11
- <sup>1</sup>Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla,
   CA, USA
- <sup>2</sup>Department of Bioengineering, University of California San Diego, La Jolla, CA, USA,
- <sup>3</sup>Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
- <sup>4</sup>Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- <sup>5</sup>Department of Health Informatics, Graduate School of Informatics, Middle East Technical
- 18 University, Ankara, Turkey
- 19 <sup>6</sup>Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK
- <sup>7</sup>Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer
   Institute, London, UK
- <sup>8</sup>Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan
- <sup>9</sup>National Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan
- <sup>10</sup>Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
- <sup>11</sup>Department of Pathology, The University of Hong Kong, Hong Kong, China
- <sup>12</sup>Ben May Department for Cancer Research, Department of Human Genetics, Comprehensive
- 27 Cancer Center, The University of Chicago, Chicago, IL, USA
- 28 <sup>13</sup>Department of Mathematics, Harvard University, Cambridge, MA, USA
- <sup>14</sup>Manchester Cancer Research Centre, The University of Manchester, Manchester, UK
- 30 <sup>15</sup>Manchester NIHR Biomedical Research Centre, Manchester, UK
- 31 <sup>16</sup>Yale Surgery Pathology Department, Yale University, New Haven, CT, USA
- 32 <sup>17</sup>Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center,
- 33 New York, USA
- <sup>18</sup>Sanford Stem Cell Institute, University of California San Diego, La Jolla, CA, USA
   <sup>35</sup>
- 36 <sup>^</sup>These authors contributed equally
- <sup>\*</sup>Correspondence should be addressed to <u>L2alexandrov@health.ucsd.edu</u> and
- 38 <u>landim@mail.nih.gov</u>
- 39

### 40 ABSTRACT

Lung cancer in never smokers (LCINS) accounts for up to 25% of all lung cancers and has been 41 associated with exposure to secondhand tobacco smoke and air pollution in observational studies. 42 Here, we evaluate the mutagenic exposures in LCINS by examining deep whole-genome 43 sequencing data from a large international cohort of 871 treatment-naïve LCINS recruited from 28 44 45 geographical locations within the Sherlock-Lung study. KRAS mutations were 3.8-fold more common in adenocarcinomas of never smokers from North America and Europe, while a 1.6-fold 46 higher prevalence of EGFR and TP53 mutations was observed in adenocarcinomas from East Asia. 47 48 Signature SBS40a, with unknown cause, was found in most samples and accounted for the largest proportion of single base substitutions in adenocarcinomas, being enriched in EGFR-mutated 49 50 cases. Conversely, the aristolochic acid signature SBS22a was almost exclusively observed in 51 patients from Taipei. Even though LCINS exposed to secondhand smoke had an 8.3% higher mutational burden and 5.4% shorter telomeres, passive smoking was not associated with driver 52 53 mutations in cancer driver genes or the activities of individual mutational signatures. In contrast, patients from regions with high levels of air pollution were more likely to have TP53 mutations 54 while exhibiting shorter telomeres and an increase in most types of somatic mutations, including 55 a 3.9-fold elevation of signature SBS4 (q-value= $3.1 \times 10^{-5}$ ), previously linked mainly to tobacco 56 smoking, and a 76% increase of clock-like signature SBS5 (q-value= $5.0 \times 10^{-5}$ ). A positive dose-57 58 response effect was observed with air pollution levels, which correlated with both a decrease in 59 telomere length and an elevation in somatic mutations, notably attributed to signatures SBS4 and SBS5. Our results elucidate the diversity of mutational processes shaping the genomic landscape 60 61 of lung cancer in never smokers.

62

### 63 **INTRODUCTION**

While cancers of the lungs are commonly associated with tobacco smoking<sup>1</sup>, prior studies have 64 indicated that between 10 and 25% of the 2.2 million lung cancer cases worldwide are found within 65 individuals that have never smoked tobacco cigarettes<sup>2,3</sup>. The prevalence of lung cancer in never 66 smokers (LCINS) varies by several notable factors, namely enrichment in females<sup>4</sup>, Asian 67 populations<sup>5</sup>, and individuals with a family history of lung cancer<sup>6</sup>. The occurrence of LCINS can 68 also differ by geographic regions, with higher rates reported in East Asia<sup>7,8</sup> and Eastern Europe<sup>9</sup> 69 when compared to countries in North America and Western Europe<sup>10</sup>. Epidemiological studies 70 71 have also identified environmental exposures that can increase LCINS risk, including exposure to secondhand smoke<sup>11</sup> and air pollution<sup>12,13</sup>. 72

73

Elucidating the mutational signatures operative within a cancer genome allows the understanding 74 of mutational processes implicated in cancer development<sup>14</sup>. Prior analyses have revealed more 75 than 100 characteristic signatures across the spectrum of human neoplasia, with putative etiology 76 assigned to approximately one third of known signatures<sup>15</sup>. However, there has been no 77 comprehensive examination of the mutational signatures operative in LCINS as prior lung cancer 78 79 whole-genome sequencing studies have focused almost exclusively on tobacco smokers from European descent<sup>16,17</sup> and they have included only a relative small number of LCINS, mostly from 80 East Asian descent<sup>18</sup>. To the best of our knowledge, our prior whole-genome sequencing study 81 encompassing 232 lung cancers from never-smokers<sup>19</sup>, which was focused on evolutionary 82 classification and its potential for personalized treatment, has been the largest examination of the 83 84 mutational landscape in LCINS.

85

86 To understand the mutational processes shaping the lung cancer genomes of never smokers, here,

- 87 we generated and analyzed deep whole-genome sequencing data from 871 treatment-naïve LCINS,
- 88 including lung cancer histologies both commonly and rarely found in never-smokers. Our large
- 89 international cohort of LCINS allowed a comprehensive evaluation of the mutagenic role of
- 90 secondhand smoke, as well as the examination and comparison of mutational signatures between
- 91 biological sexes, ancestries, and 28 geographic regions with different levels of air pollution.

### 92 **RESULTS**

### 93 The Sherlock-Lung never-smoking lung cancer cohort

As part of the Sherlock-Lung study<sup>20</sup>, a total of 871 treatment-naïve never-smoking lung cancer 94 95 cases were whole-genome sequenced with a mean coverage of 88x and 35x for tumor and matched 96 germline samples, respectively. Patients were recruited from 28 different locations across four 97 continents (Fig. 1a) and were predominantly female (n=688; 79.0%). Patients from North America 98 and Europe (NA/EU; n=541; 62.1%) mostly clustered with the EUR super-sample from the 1,000 Genomes Project<sup>21</sup> (472/541; 87.2%), and patients from East Asia (AS; n=309; 35.5%) clustered 99 100 exclusively with the EAS super-sample (Fig. 1b). Patients of European descent were almost 101 exclusively recruited from Europe, Russia, USA, and Canada, while patients from Asian descent 102 were recruited mainly in Hong Kong, Taipei, Korea, and Canada (Supplementary Table 1). Most 103 patients were diagnosed with adenocarcinomas (n=737; 84.6%) or carcinoid tumors (n=61; 7.0%). In addition, we report the genomic landscapes of 31 squamous cell carcinomas and additional rarer 104 105 histologies, including 13 adenosquamous carcinomas, 5 large cell carcinomas and 24 tumors with 106 uncertain histological subtype (Supplementary Table 1). Information on passive smoking was 107 collected for 458 patients, with 250 exposed and 208 not exposed to secondhand tobacco smoke. 108 No subjects included in the study reported occupational exposure to mutagenic agents.

109

### 110 Mutational patterns of lung cancer in never smokers

The median tumor mutational burden (TMB) was 5,068 for single base substitutions (SBSs; range 393-151,385), 279 for small insertions and deletions (IDs; range 14-10,474), and 105 for structural variants (SV; range 1-1,103 **Fig. 1***c*), with differences across histologies and geographical locations. Similarly, the median percentage of genome aberration was 55.3%, with clear variances

115 across histologies and geographical areas (Fig. 1c). To identify the mutational processes operative in LCINS, we performed *de novo* extraction<sup>22</sup> of mutational signatures for SBS, ID, doublet base 116 117 substitutions (DBS), copy number (CN) alterations, and structural variants (SV: Supplementary 118 **Tables 2-6**). Eleven *de novo* SBS signatures were extracted and further decomposed into 18 119 previously identified signatures from the Catalogue of Somatic Mutations in Cancer (COSMICv3.4) reference signature database<sup>23</sup> (Supplementary Fig. 1; Supplementary Table 7). 120 The unprecedented size of the cohort allowed us to refine the prevalence and intensity of the 121 122 signatures involved in LCINS, with several signatures identified for the first time in LCINS, 123 including signature SBS40a, recently extracted in clear cell renal cell carcinomas but shown to be active in multiple cancer types<sup>15,24</sup>. Other SBS signatures not previously seen in LCINS included 124 unknown etiology signatures SBS12, SBS33, and SBS39 as well as the aristolochic acid-related 125 126 signature SBS22a and tobacco smoking-associated signatures SBS4 and SBS92 (Fig. 1d). 127 Additionally, the mismatch repair deficiency-associated signatures SBS21 and SBS44 were 128 detected in one lung adenocarcinoma case, which had 10,474 indels and was confirmed by 129 MMRDetect<sup>25</sup> as microsatellite unstable cancer. Analysis of indels and doublet base substitutions 130 revealed a new compendium of mutational signatures operative in LCINS (Supplementary Figs. 131 2-3; Supplementary Tables 8-9). Specifically, a novel ID signature was identified (termed, ID24), characterized by short microhomology deletions, whereas several ID and DBS signatures were 132 identified for the first time in LCINS, including ID6, ID10, ID11, ID14, ID19, ID23, DBS5, DBS6, 133 134 and DBS13. De novo extraction of signatures of large mutational events revealed four CN 135 (Supplementary Fig. 4) and four SV (Supplementary Fig. 5) signatures, which were subsequently decomposed into the recently described COSMICv3.4 reference signatures<sup>26-29</sup> 136 137 (Supplementary Tables 10-11).

### 138 Mutational landscape of lung adenocarcinoma in never smokers

The genomic landscape of the 737 lung adenocarcinomas from never smokers showed a 139 140 remarkable heterogeneity for both SBS and CN alterations (Fig. 2a). Approximately 4.9% of 141 adenocarcinomas (36/737) harbored tobacco-associated signature SBS4, while the most prevalent signature was SBS40a, of unknown etiology, which contributed 28.2% of all substitutions. 142 143 Interestingly, a cluster of 25 hypermutated samples (>25,000 mutations) with high proportions of SBS4 and APOBEC-associated signatures SBS2 and SBS13 was identified (Fig. 2a-b). 144 145 Additionally, a smaller subset of 11 cases harboring signatures SBS3 and ID6, both linked to 146 homologous recombination deficiency (HRD), was also identified. The presence of HRD was further evaluated using CHORD<sup>30</sup> and HRDetect<sup>31</sup>, which jointly predicted six of the cases as 147 148 HRD, with two additional cases predicted as HRD exclusively by CHORD (Supplementary Fig. 6).

149

150

Comparisons between patients from different regions revealed differences in somatic mutagenesis 151 152 (Fig. 2*c-d*). Notably, signature SBS22a (previously known as SBS22, and recently renamed<sup>24</sup>) was enriched in patients from East Asia (Fig. 2c). This enrichment was also observed after removing 153 154 the patients from Canada with EAS ancestry (Supplementary Fig. 7; Methods), which encompassed most of the patients with EAS ancestry not residing in Asia (35/40, 87.5%; Fig. 1b). 155 156 Further, SBS22a was found almost exclusively in patients from Taipei (32/36 SBS22a-positive cases, 88.9%). Although SBS22a has been associated with aristolochic acid exposure in liver, 157 bladder, and kidney cancers<sup>32,33</sup>, this is the first evidence of aristolochic acid causing mutations in 158 159 lung cancer. Moreover, SBS22a also showed a significant co-occurrence with SBS12 in patients 160 from East Asia (OR=4.55; p-value= $1.2 \times 10^{-4}$ ). SBS12 is commonly found in gastrointestinal

161 cancers, especially cancers of the livers<sup>15,34</sup> and kidneys<sup>24</sup>, with a consistent enrichment of the 162 signature in patients from East Asia<sup>24,34</sup>.

163

164 Several signatures of indels and large genomics alterations differed across regions (Extended Data Fig. 1a), with ID3, CN20, SV2, SV4, SV6, and SV9 being more prevalent in patients from 165 East Asia, whereas three additional SV signatures, all linked primarily with non-clustered 166 alterations, SV5, SV7, and SV10, were enriched in North American and European patients. 167 168 Interestingly, CN20 was previously found elevated in Black TCGA patients but not in Asian patients when compared to White patients<sup>26</sup>. Additionally, signatures SBS4 and ID3 showed a 169 170 difference between males and females across the spectrum of variant classes, with a notably higher prevalence in males, whereas ID9 was enriched in females (Extended Data Fig. 1b). 171

172

As in prior LCINS studies<sup>10</sup>, EGFR and TP53 harbored the most driver mutations, with 52.2% and 173 174 30.5% mutated in adenocarcinomas, respectively, whereas KRAS was only mutated in 6.5% of 175 samples. EGFR and TP53 mutations were enriched in patients from East Asia, as previously reported<sup>35</sup>, and KRAS mutations were elevated in North American and European patients (Fig. 2e-176 177 f and Extended Data Fig. 1*c-e*). No differences were found for driver mutations between males and females for adenocarcinomas (Extended Data Fig. 1f). Interestingly, for EGFR-mutated 178 tumors, a significant increase in TMB was observed for those TP53-wild-type (q-179 value= $1.2 \times 10^{-4}$ ), whereas a decrease was found for *TP53*-mutated cases (q-value=0.15; 180 **Extended Data Fig. 1g**). In addition, while analyzing EGFR-mutated cases specifically, we 181 182 identified a high enrichment in the prevalence of signature SBS40a, along with other signatures of 183 multiple variant types (Extended Data Fig. 1*h*).

184 Most driver mutations in EGFR, TP53, and KRAS were probabilistically assigned to signatures SBS5 and SBS40a (Fig. 2g), with the proportion of driver mutations significantly higher than 185 expected according to their prevalence in the overall adenocarcinoma cohort (OR=2.55; p-186 187 value= $9.8 \times 10^{-22}$ ; Fig. 2d). Prior analyses have shown that SBS4 generates the majority of driver mutations in *KRAS* in tobacco smokers<sup>36</sup>. In our samples, SBS4 contributed only ~10% of KRAS 188 mutations. Most driver indels, especially in EGFR (mostly exon 19 deletions; 150/173, 86.7%), 189 were probabilistically assigned to signature ID8 (Fig. 2h), which has been previously related to 190 191 radiation exposure<sup>37</sup>. Despite contributing a significant number of mutations in adenocarcinomas 192 (Fig. 2d), APOBEC-associated signatures SBS2 and SBS13 generate a significantly lower number 193 of driver mutations in EGFR, TP53, and KRAS (OR=0.28; p-value= $2.8 \times 10^{-14}$ ) in comparison to 194 their prevalence in the overall adenocarcinoma cohort, with most APOBEC-associated mutations 195 being TP53 point mutations in a small number of samples (Fig. 2g).

196

### 197 Mutational landscape of lung carcinoids in never smokers

198 Carcinoid tumors were the second most common histology, with all samples originating from 199 North American and European patients except one case from Taipei (Supplementary Table 1), 200 and only one case harboring signature SBS4. Carcinoids presented a lower number of single base 201 substitutions (p-value= $3.3 \times 10^{-29}$ ), copy number (p-value= $2.6 \times 10^{-32}$ ), and structural variants (pvalue= $4.2 \times 10^{-26}$ ) compared to adenocarcinomas, as well as longer telomeres (p-value= $2.0 \times 10^{-6}$ ; 202 203 Extended Data Fig. 2). SBS5 accounted for 55.7% of all mutations in carcinoids in contrast to 27.0% in the adenocarcinomas (p-value<2.2×10<sup>-16</sup>; Fig. 1d and Extended Data Fig. 3a). In 204 comparison to adenocarcinomas, carcinoids showed 3.39-fold lower TMB (Extended Data Fig. 205 206 2a), with depletion of signatures SBS2, SBS5, SBS12, and SBS13 (Extended Data Fig. 4a).

Nevertheless, we observed an enrichment in signature SBS8, previously linked to nucleotide excision repair<sup>38</sup> and late replicating regions<sup>39</sup>. Interestingly, SBS8 was a relatively minor signature in adenocarcinomas (**Fig. 1***d*) but present in the majority of carcinoids (35/61), where it contributed 11.0% of all mutations (**Extended Data Fig. 3***a*). As lung carcinoids are thought to originate from neuroendocrine cells producing hormones and hormone-like substances<sup>40</sup>, the presence of SBS8 is perhaps not surprising as this mutational signature is commonly observed in hormone-dependent cancers such as breast<sup>41</sup> and prostate<sup>15</sup> adenocarcinomas.

214

Additionally, three ID signatures and the diploid CN1 signature were found enriched in carcinoids,
whereas several different signatures were enriched in adenocarcinomas, including two DBS, four
ID, and most CN and SV signatures (Extended Data Fig. 3b and 4a), as expected due to the lower
number of large genomic aberrations of this histological subtype of LCINS (Extended Data Fig.
2a). No *EGFR* or *KRAS* driver mutations were found in carcinoid histology, whereas an
enrichment was found for driver mutations in *ARID1A* (Extended Data Fig. 3c and 4b-d).

221

### 222 Mutational landscape of lung squamous cell carcinomas in never smokers

Squamous cell carcinomas accounted for 3.6% of LCINS (31/871), with 13 samples harboring
tobacco-associated signature SBS4. In comparison with adenocarcinomas, squamous cell
carcinomas showed an elevated burden of SBS, DBS, and ID, in contrast to a similar landscape of
large genomic alterations and telomere lengths (Extended Data Fig. 2). Several signatures showed
higher prevalence compared to adenocarcinomas, including SBS3, SBS4, SBS92, and SV7
(Extended Data Fig. 5*a*-*c* and 6*a*). *TP53* was the most prevalent driver mutation (58.1% of cases;
Extended Data Fig. 5*d*) and was found enriched in LCINS squamous cell carcinomas compared

to adenocarcinomas, along with mutations in *LRP1B*, *PIK3CA*, and *PTEN* (Extended Data Fig.
6b-g). In contrast, *EGFR* mutations were rarely observed in squamous cell carcinomas, as
previously reported<sup>42</sup> (Extended Data Fig. 6d).

233

### 234 SBS4 in lung tumors from never smokers

235 Tobacco-associated signature SBS4 was found active in 56 LCINS tumors (6.4%), and was the predominant signature in 39 of them (69.6%) and in many hypermutated cases (5.51-fold higher 236 median SBS burden in SBS4+ cases; Extended Data Fig. 7a-b). Similarly, signature SBS92, 237 recently linked to tobacco smoking in bladder<sup>22,43</sup> and other cancer types<sup>44</sup>, was also active in four 238 239 SBS4+ tumors, and found significantly enriched in SBS4+ cases (p-value= $2.1 \times 10^{-4}$ ; Extended 240 **Data Fig.** 7b). Tumors presenting active SBS4 also showed a significant enrichment of previous ID and DBS signatures linked to tobacco smoking, namely ID3 (p-value= $1.1 \times 10^{-22}$ ) and DBS2 241 242 (p-value= $5.0 \times 10^{-7}$ ; Extended Data Fig. 7*c-d*). Additionally, SBS4 in LCINS exhibited the same genome topography characteristics as SBS4 in smokers<sup>45</sup>, including enrichment in late replicating 243 244 regions, periodicity in the vicinity of nucleosomes, and strong genic and transcriptional strand asymmetries (Extended Data Fig. 8). 245

246

In principle, detecting SBS4 in never-smokers can be due to misannotation of tobacco smoking status. The observed SBS4 prevalence increase in males and lung squamous cell carcinomas indicates that some samples might have been incorrectly annotated as never smokers. Nevertheless, the 56 LCINS tumors with SBS4 exhibited statistically different driver mutations when compared to previously generated lung cancers from tobacco smokers<sup>36</sup> (**Extended Data Fig. 7***e*). Specifically, the LCINS samples had fewer mutations in *KRAS* (OR=0.41; p-

value=0.021) and an enrichment of *EGFR* p.L858R hotspot mutations (OR=29.35; pvalue= $4.1 \times 10^{-4}$ ). These differences indicate that, in addition to possible misannotation, other exogenous processes may be generating SBS4 in these never smokers. As prior work has shown that SBS4 can be found in lifelong non-smokers exposed to different environmental mutagens, including occupational history of coal tar work<sup>46</sup> and indoor air pollution<sup>47</sup>, we evaluated whether SBS4 in this cohort, as well as mutations in other samples, can be generated by either secondhand exposure to tobacco smoking or by high levels of air pollution.

260

### 261 Passive smoking has low mutagenicity in LCINS

262 To understand the mutational processes activated by secondhand tobacco smoking, we compared 263 the genomic landscapes of 250 LCINS from passive smokers to 208 LCINS from individuals who 264 were not exposed to secondhand smoke. We observed an increase of SBS mutations in passive smokers (Fig. 3*a*), as well as a decrease in tumor/normal telomere length ratio (Fig. 3*b*). Although 265 266 not significant, the directionality of these associations with passive smoking was consistent after 267 adjustment for other covariates, encompassing age, sex, genetic ancestry, histology, and tumor 268 purity -8.3% increase and 5.4% decrease in the magnitude of regression coefficients after 269 covariate correction, respectively (Fig. 3c-d). Almost identical results were observed when we 270 restricted the analyses to the lung adenocarcinomas from never smokers (Supplementary Fig. 8), 271 and when the principal components from the ancestry analysis were used instead of the ancestry 272 labels for adjustment (Supplementary Table 12; Methods). However, this increase in mutation 273 burden was not specifically associated with any mutational signature (Fig. 3e) or mutation type 274 (Fig. 3f). In addition, no significant differences were found for mutations in any cancer driver 275 genes (Fig. 3g), nor for the burden of ID, DBS, SV, or CN segments (Extended Data Fig. 9a-e)

or the presence of signatures derived from these mutation types (Extended Data Fig. 9*f*). Amongst
the 250 cases identified as exposed to secondhand smoke, only three (1.2%) displayed signature
SBS4 (OR=0.62; p-value=0.71), each with a contribution exceeding 20% and at least 500
mutations attributed to SBS4. Moreover, only two of the 281 driver mutations found in secondhand
smoke-exposed samples were assigned to SBS4 with a probability above 50%, including a *TP53*missense mutation (p.Val157Phe) and a missense mutation (p.Val409Leu) in *NF1*.

282

To evaluate if we were unable to assign SBS4 to other secondhand smoke-exposed cases due to 283 284 low levels of the signature, we synthetically injected SBS4 mutations using simulations at different 285 levels into the mutational profiles of the 247 passive smoker cases that lacked SBS4 and assessed 286 the number of samples where SBS4 was detected (Supplementary Fig. 9). We were able to detect 287 SBS4 in around a guarter of simulated samples, if it contributed at least 5% of all mutations within a sample. Moreover, SBS4 was detectable in almost every sample when the signature accounted 288 289 for more than 10% of mutations. These simulation results agree with the levels of SBS4 observed 290 in the set of SBS4+ samples, where SBS4 is contributing above 10%. Thus, although SBS4 could 291 have been missed in some secondhand smoke exposed LCINS, this signature would be likely 292 contributing less than 5% of mutations in these cancers. Overall, our simulations demonstrate that 293 it is unlikely that exposure to secondhand smoke accounts for SBS4, whereas the modest increase 294 in overall SBS mutations suggests that passive smoking has low mutagenicity.

295

### 296 Air pollution is associated with increased somatic mutations in LCINS

Given the recent evidence of the role of air pollution in lung carcinogenesis<sup>12,48</sup>, we assessed
whether atmospheric air pollution, quantified by the environmental particulate matter measuring

299  $\leq$ 2.5 µm (PM<sub>2.5</sub>), had an effect on the accumulation of somatic mutations in LCINS. Yearly PM<sub>2.5</sub> estimates from 1998-2021 were obtained for the 853 LCINS cases with annotated country of 300 301 residence using a hybrid model combining satellite-based measurements of aerosol optical depth 302 with chemical transport modeling and ground-based observations (Methods)<sup>49</sup>. Considering the distribution of PM<sub>2.5</sub> estimates across the cohort, a threshold of 20  $\mu$ g/m<sup>3</sup> was used to separate 303 304 patients diagnosed in regions with high and low levels of pollution (Supplementary Fig. 10). LCINS originating from areas with high PM<sub>2.5</sub> levels exhibited increased burdens of SBS (13.0%), 305 306 DBS (8.3%), and ID mutations (7.6%; Fig. 4a), along with telomere shortening (Fig. 4b), even 307 after accounting for age, sex, genetic ancestry, histology, and tumor purity (Fig. 4c-d; 308 Supplementary Table 12). No enrichments were identified for the numbers of SV or CN segments 309 after corrections (Extended Data Fig. 10a-b). In order to determine whether higher levels of 310 pollution lead to an increase in somatic mutagenesis (*i.e.*, a dose-response effect), we calculated individual estimates of PM<sub>2.5</sub> per lung cancer patient (Methods). Consistent with a dose-response 311 effect, we found statistically significant positive correlations of PM<sub>2.5</sub> with the burden of SBS, 312 313 DBS, and ID (Fig. 4e-g), as well as a negative correlation with telomere length (Fig. 4h), further 314 corroborating the dose-response relationship of outdoor air pollution and somatic mutations in 315 LCINS.

316

Several mutational signature-specific associations with individual PM<sub>2.5</sub> estimates were found after adjusting for covariates (**Fig.** 5*a*). These included clock-like signature SBS5 (OR for 10  $\mu$ g/m<sup>3</sup> of PM<sub>2.5</sub>=1.76; q-value=5.0 × 10<sup>-5</sup>) as well as signatures SBS4 (OR=3.86; q-value=3.1 × 10<sup>-5</sup>) and ID3 (OR=1.63; q-value=5.1 × 10<sup>-4</sup>; **Fig.** 5*b*; **Supplementary Table 12**). Furthermore, doseresponse effects were also observed for these signatures, with a significant positive correlation

322 between the total numbers of mutations assigned to a given signature and the individual PM<sub>2.5</sub> 323 estimates (Fig. 5*c-e*). Specifically, a unit  $(1\mu g/m^3)$  increase of PM<sub>2.5</sub> was associated with a 2.3% increase in SBS5-associated mutations, 12.0% in SBS4-associated mutations, and 6.0% in ID3-324 325 associated mutations, independent of other covariates. No associations were found with DBS, CN, 326 or SV signatures (Fig. 5*a*; Extended Data Fig. 10*c*). Patients in regions with high PM<sub>2.5</sub> exposure were 1.6 times more likely to have TP53 mutations and 2.5 times less likely to have CTNNB1 327 328 mutations (Fig. 5*f-h*). Overall, these results indicate that elevated air pollution levels are associated 329 with an increase in both somatic mutations contributing to specific mutational signatures as well 330 as an increased prevalence of TP53 mutations.

331

### 332 DISCUSSION

This study presents the most extensive mutational analyses of whole-genome sequenced lung 333 334 cancers in never smokers. Our results reveal multiple mutational signatures and mutated cancer 335 driver genes whose frequencies differ across lung cancer histologies, regions, and exposures. 336 Particularly noteworthy is our finding of the aristolochic acid signature SBS22a in patients from 337 Taipei, possibly shedding light on one of the previous unappreciated environmental factors contributing to the accumulation of mutations in LCINS from East Asia. Similarly, multiple 338 339 signatures of indels and large genomics alterations, most with unknown etiology, were found to 340 differ across regions, further highlighting the likely existence of additional population-specific 341 exposures and other factors contributing to LCINS. Notably, SBS40a, with an unknown cause, and previously associated with kidney cancer<sup>24</sup>, accounted for the largest proportion of substitutions in 342 343 adenocarcinomas, thus indicating the existence of a globally widespread and previously 344 unappreciated mutagenic process, likely of endogenous origin.

345

346 Prior epidemiological research<sup>11</sup> has established that passive smoking can be associated with a 347 modest heightened risk for developing LCINS. In line with the observational research, our analysis 348 of 458 patients with known exposure to passive smoking uncovered only minimal indications of elevated mutagenesis amongst individuals exposed to secondhand smoke. As in previous 349 350 epidemiological studies, the data about second-hand tobacco smoking exposure was derived from 351 questionnaires and clinical datasets, and varied across individuals, going from very detailed 352 (during childhood, at work, or with a smoking spouse) to just binary yes/no exposure status. Thus, 353 low exposure levels or very remote exposure (during childhood) may contribute to our findings of 354 low mutagenicity. Nevertheless, our results are also consistent with a recent study in 291 Japanese

LCINS patients with extensive information on passive smoking<sup>50</sup>. Additional non-mutagenic carcinogenesis could be contributing to the observed rise in lung cancer in those exposed to secondhand smoke.

358

359 Our investigation of the mutagenic role of outdoor air pollution relied on an average country- and 360 state/province-level quantification of PM<sub>2.5</sub> that did not provide granularity within these 361 geographical regions or consideration for seasonal variabilities or indoor air pollution levels. The exposure was linked to the subjects' residence at the time of lung cancer diagnosis and may not 362 reflect their lifetime exposure, and the assigned exposures for the patients recruited to this study 363 364 may systematically differ from the average country, state, province, or city level pollution levels. 365 As such, these associations should be interpreted with caution. Despite these limitations, our 366 findings suggest that LCINS in individuals from areas with elevated air pollution have a higher prevalence of TP53 mutations while exhibiting shorter telomeres and heightened mutagenesis, 367 368 notably attributed to signatures SBS4 and SBS5. Consistent with our findings, a previous study 369 comparing Chinese regions with different levels of air pollution reported an increase in TP53 and 370 total somatic mutations in the highly polluted region of Xuanwei, with a C>A enriched mutational pattern resembling signature SBS4<sup>51</sup>. 371

372

In principle, mutations linked to clock-like signature SBS5 that accumulate in LCINS with the increase of PM<sub>2.5</sub> could be due to additional DNA damage that accumulates in people living in more polluted areas. In addition, considering the significant telomere shortening observed with high levels of PM<sub>2.5</sub> exposure, the clock-like somatic mutations could also be a readout of a promotion mechanism where lung cells are undergoing more cell divisions in individuals residing

in highly polluted areas. Consistently, a recent experimental study<sup>48</sup> showed that air pollution acts as a tumor-promoting inflammatory agent, demonstrating that short-term exposure to PM<sub>2.5</sub> is not strongly mutagenic in mice, although leading to an elevation of signature SBS5 and reduced telomeres (**Extended Data Fig. 11**). Future studies with long-term PM<sub>2.5</sub> exposures and higher number of replicates will be required to experimentally validate the role of outdoor air pollution as a driver of both mutations and inflammation leading to tumorigenesis.

384

While the association between SBS4 and PM2.5 potentially encompasses the effects of atmospheric 385 386 pollution exposure in LCINS, the small proportion of cases affected by SBS4 (6.4% of all samples) 387 and the high number of mutations in SBS4+ cancers (21,785 on average) could indicate extreme 388 events of outdoor, indoor, or occupational air pollution. Indeed, such events have been previously 389 reported, for example, SBS4 was found in the lung cancers of never-smoking Chinese women that often cook with smoky coal in poorly ventilated houses<sup>47</sup>, and it is likely that severe levels of 390 391 pollution are more common in countries with overall higher air pollution levels. Lastly, it is also 392 possible that the self-reported smoking status was inaccurate, as previously shown in other cohorts after biochemical verification<sup>52</sup>, and that some SBS4 cases from smokers were misannotated as 393 394 never smokers, albeit it is unlikely that such misannotation will exhibit any correlation with air 395 pollution. Notwithstanding, the reported associations between air pollution and somatic mutations 396 remained unaffected when all SBS4 mutations were excluded from our analysis (Extended Data 397 Fig. 12).

398

Overall, the unprecedented size of our global cohort allowed us to refine the prevalence andintensity of the mutational signatures and driver mutations involved in LCINS, and their variability

- 401 across histologies, genetic ancestries, and geographical locations. Although LCINS appear to be
- 402 dominated by endogenous processes, our results indicate exposure to aristolochic acids in Taipei's
- 403 samples, a low mutagenicity of passive smoking, and a role of air pollution as both a mutagenic
- 404 initiator and promoter of neoplastic expansion in LCINS.
- 405

### 406 FIGURE LEGENDS

Fig. 1. Overview of the Sherlock-Lung cohort of lung cancers in never smokers. a, 407 Geographical distribution of the 871 patients across four continents and 28 geographic locations. 408 409 b, Clinical characterization based on histology, genetic ancestry, geographical region, biological 410 sex, and passive smoking status. c, Prevalence of mutations, percentage of genome altered, and 411 structural variants across geographic locations and stratified based on histology. Left panel, dots 412 represent median values for the three genomic alterations individually per country and histology. Right panel, dots represent individual tumors, colors different histology types, and horizontal 413 414 purple lines median values across all histologies. d, Landscape of mutational signatures across 415 histologies and somatic variant classes, including single base substitutions (SBS), doublet base 416 substitutions (DBS), small insertions and deletions (ID), copy number alterations (CN), and 417 structural variants (SV). The size and color of the dots represent the percentage of mutations 418 contributed by the signature in all samples sharing the same histology (top panel) or the percentage of samples of a histological type where a particular signature is active (bottom panel). AS: East 419 420 Asian geographical regions, EAS: East Asian genetic ancestry super-sample, EUR: European 421 genetic ancestry super-sample, LUAD: lung adenocarcinomas, LUSC: lung squamous cell 422 carcinomas, NA/EU: North America and Europe geographical regions.

423

# Fig. 2 Repertoire of mutational signatures and driver mutations in LCINS adenocarcinomas. a, Distribution of the most prevalent signatures per sample according to the number of single base substitutions (SBS) and percentage of genome aberrated. b, Activity of SBS mutational signatures across samples, representing the total number of mutations attributed to each signature in a given

428 sample. Dots represent individual samples and purple horizontal bars median values. The numbers

429 on the bottom indicate the total number of samples where a particular signature was found active (blue) and the total number of LCINS adenocarcinoma samples (green). c, Regional differences 430 across signatures. Volcano plot indicating enrichment of SBS signatures in patients from East 431 432 Asian (AS) and North American/European regions (NA/EU) in LCINS adenocarcinomas (top 433 panel) and bar plot indicating prevalence by geographical region (bottom panel). Horizontal lines 434 marking statistically significant thresholds were included at 0.05 (dashed orange line) and 0.01 435 FDR levels (dashed red line). d, Total number of mutations assigned to specific SBS signatures for patients from East Asia or North America and Europe. e, Volcano plot indicating enrichment 436 437 of mutations in driver genes affecting specific LCINS adenocarcinomas. Blue-colored genes were 438 enriched in patients from North America and Europe, whereas red-colored genes were enriched in 439 patients from East Asia. f, Frequency of LCINS adenocarcinoma cases harboring driver mutations 440 in the driver genes significantly differently mutated between geographical regions (EGFR, TP53, and KRAS) g, Proportion of driver mutations affecting EGFR, TP53, and KRAS probabilistically 441 assigned to each of the SBS mutational signatures identified in the LCINS adenocarcinoma cohort. 442 443 The numbers indicate the total number of driver single base substitutions found in each of the 444 genes.

445

Fig. 3. Passive smoking influence in the genomic landscape of LCINS. a-d, Differences in base substitution burden and tumor-to-normal telomere length ratio using univariate comparisons (a and b) as well as multivariable linear regressions considering clinical and epidemiological covariates (c and d), including age, sex, genetic ancestry, histology, and tumor purity. e, Volcano plot indicating enrichment of mutational signatures derived from SBS mutations in passive vs. non-passive smokers. Horizontal lines marking statistically significant thresholds were included

at 0.05 (dashed orange line) and 0.01 FDR levels (dashed red line). f, Comparison of the mutations
belonging to each of the six main SBS mutation subtypes in passive vs. non-passive smokers. g,
Volcano plot indicating enrichment of mutations in driver genes affecting specific LCINS tumors.

Fig. 4. Mutagenic effects of PM<sub>2.5</sub> exposure in LCINS. a, Quantification of tumor mutational 456 457 burden according to different mutation types, including SBS, DBS, and ID, for patients living in geographical regions with high and low PM<sub>2.5</sub> exposure levels (threshold defined at 20  $\mu$ g/m<sup>3</sup>; only 458 459 samples for which the country of origin was known (n=853) are included). **b**, Quantification of the 460 ratio of telomere lengths for tumor and normal samples across high and low PM<sub>2.5</sub> exposed cases. 461 c-d, Forest plots corresponding to multivariable linear regressions considering high/low PM<sub>2.5</sub> 462 exposure group, age, sex, genetic ancestry, histology, and tumor sample purity as covariates and 463 tumor mutational burden for the specific mutation type, SBS, DBS, ID (c), or telomere length ratio (d) as independent variables. e-h, Scatter plots showing significant correlations between individual 464 465 sample estimates of  $PM_{2.5}$  exposure and tumor mutational burden for SBS (e), DBS (f), ID (g), and 466 telomere length ratio (**h**).

467

Fig. 5. Associations between PM<sub>2.5</sub> exposure and specific mutational signatures affecting LCINS tumors. **a**, Enrichment analysis of the presence of mutational signatures derived from SBS, DBS, and ID with PM<sub>2.5</sub> exposure levels for all samples for which the country of origin was known (n=853). Horizontal lines marking statistically significant thresholds were included at 0.05 (dashed orange line) and 0.01 FDR levels (dashed red line). The odds ratios for the increase/decrease of 10 µg/m<sup>3</sup> of PM<sub>2.5</sub> estimates are shown. **b**, Detailed forest plots for the logistic regression models corresponding to signatures SBS4, SBS5, and ID3. **c-e**, Scatter plots assessing

- 475 dose-response effect between individual sample estimates of PM<sub>2.5</sub> exposure and mutations
- 476 assigned to signatures SBS4 (c), SBS5 (d), and ID3 (e). f, Enrichment analysis of the presence of
- 477 mutations in driver genes with  $PM_{2.5}$  exposure levels. g-h, Detail of the enrichment of *TP53* (g)
- 478 and *CTNNB1* (**h**) driver mutations in high and low pollution regions, respectively.

479

### 480 EXTENDED DATA FIGURE LEGENDS

Extended Data Fig. 1. Association of mutational signature prevalence and driver mutations 481 with geographical regions, biological sexes, and EGFR mutation status in LCINS 482 483 adenocarcinoma cases. a, DBS, ID, CN, and SV mutational signatures enrichment analysis with 484 geographical regions. Horizontal lines marking statistically significant thresholds were included 485 at 0.05 (dashed orange line) and 0.01 FDR value levels (dashed red line). Blue-colored signatures 486 were enriched in North American and European patients, whereas red-colored signatures were enriched in East Asian patients. b, SBS, DBS, ID, CN, and SV mutational signatures enrichment 487 488 analysis with biological sexes. Blue-colored signatures were enriched in males, whereas red-489 colored signatures were enriched in females. c-e, Detail of the enrichment of EGFR (c), TP53 (d), 490 and KRAS (e) driver mutations in North American and European vs. East Asian LCINS 491 adenocarcinoma cases. f, Driver mutations enrichment analysis with biological sexes. Blue-492 colored genes were enriched in males, whereas red-colored genes were enriched in females. h, SBS, DBS, ID, CN, and SV mutational signatures enrichment analysis with EGFR mutation status. 493 494 Blue-colored signatures were enriched in EGFR mutant tumors, whereas red-colored signatures 495 were enriched in *EGFR* wild-type tumors.

496

497 Extended Data Fig. 2. Tumor mutational burden differences in LCINS across histologies. a498 b, Quantification of tumor mutational burden according to different mutation types, including SBS,
499 DBS, ID, number of copy number segments, and structural variants (a), as well as telomere length
500 ratios between tumor and normal samples (b) across histologies.

501

### 502 Extended Data Fig. 3. Repertoire of mutational signatures and driver mutations in LCINS

**carcinoids. a-b**, Mutational signature landscape for SBS (**a**) and ID (**b**) mutation types, including absolute and relative number of mutations assigned to each mutational signature, unsupervised clustering based on the signature contributions, and sample-level annotations of sex, genetic ancestry, and accuracy of signature reconstruction based on cosine similarity. **c**, Driver mutations landscape, including different types of genomic alterations, as well as sample-level annotations of sex, genetic ancestry, histology, and tumor purity.

509

Extended Data Fig. 4. Association of mutational signature prevalence and driver mutations with adenocarcinoma and carcinoid histology in LCINS cases. a-b SBS, DBS, ID, CN, and SV mutational signatures, and driver mutations (b) enrichment analysis. Horizontal lines marking statistically significant thresholds were included at 0.05 (dashed orange line) and 0.01 FDR value levels (dashed red line). Blue-colored signatures/genes were enriched in adenocarcinomas, whereas green-colored signatures/genes were enriched in carcinoids. c-d, Detail of the enrichment of *TP53* (c) and *ARID1A* (d) driver mutations in carcinoid vs. adenocarcinoma LCINS.

517

**Extended Data Fig. 5. Genomic landscape in LCINS squamous cell carcinomas. a-c**, Mutational signature landscape for SBS (**a**), DBS (**b**), and ID (**c**) mutation types, including absolute and relative number of mutations assigned to each mutational signature, unsupervised clustering based on the signature contributions, and sample-level annotations of sex, genetic ancestry, and accuracy of signature reconstruction based on cosine similarity. **d**, Driver mutations landscape, including different types of genomic alterations, as well as sample-level annotations of sex, genetic ancestry, histology, and tumor purity.

525

Extended Data Fig. 6. Association of mutational signature prevalence and driver mutations 526 527 with adenocarcinoma and squamous cell carcinoma histology in LCINS cases. a-b SBS, DBS, 528 ID, CN, and SV (a) mutational signatures, and driver mutations (b) enrichment analysis. 529 Horizontal lines marking statistically significant thresholds were included at 0.05 (dashed orange 530 line) and 0.01 FDR value levels (dashed red line). Blue-colored signatures/genes were enriched in adenocarcinomas, whereas red-colored signatures/genes were enriched in squamous cell 531 532 carcinomas. c-f, Detail of the enrichment of TP53 (c), EGFR (d), LRP1B (e), PTEN (f) and 533 *PIK3CA* (g) driver mutations in squamous cell carcinoma vs. adenocarcinoma LCINS. 534 535 Extended Data Fig. 7. Genomic landscape of 56 LCINS tumors presenting SBS4 activity. a, 536 Tumor mutational burden differences between SBS4 positive and negative LCINS tumors for SBS, DBS, ID, CN segments, and SV events. **b-d**, Mutational signature landscape for SBS (**b**), DBS (**c**), 537 538 and ID (d) mutation types, including absolute and relative number of mutations assigned to each 539 mutational signature, unsupervised clustering based on the signature contributions, and sample-540 level annotations of sex, genetic ancestry, passive smoking, and accuracy of signature 541 reconstruction based on cosine similarity. e, Driver mutations landscape, including different types 542 of genomic alterations, as well as sample-level annotations of sex, genetic ancestry, histology, and 543 tumor purity.

544

Extended Data Fig. 8. Topographical characteristics of 56 LCINS and 68 lung cancer from
smokers presenting SBS4 activity. a-b, Distribution of SBS4 mutations with replication timing
in our cohort of never smokers (a) and in the smokers from the PCAWG cohort (b). Data are

548 separated into deciles, with each segment harboring 10% of the observed replication time signal in the x-axis, and the normalized mutational density displayed in the y-axis. c-d, Association of 549 550 SBS4 mutations with nucleosome occupancy in never smokers (c) and smokers (d). The solid blue 551 line represents real somatic mutations, whereas the dashed grey line indicates the distribution of 552 simulated mutations. Both lines show the average nucleosome signal in the y-axis, using a genomic 553 window of 2 kilobases centered around the SBS4-associated mutations in the x-axis. e-f, Strand 554 asymmetry of SBS4-associated mutations in comparison to simulations and considering lagging 555 and leading DNA strands, transcribed and untranscribed DNA regions and genic and intergenic 556 genomic locations in never smokers (e) and smokers (f).

557

**Extended Data Fig. 9. Passive smoking influence in the landscape of ID, DBS, CN, and SV in LCINS. a-e**, Differences in DBS, ID, CN, and SV burden using univariate comparisons (**a**) as well as multivariable linear regressions considering clinical and epidemiological covariates (**b-e**), including age, sex, genetic ancestry, and tumor purity. **f**, Volcano plots indicating enrichment of mutational signatures derived from DBS, ID, CN, and SV alterations. Horizontal lines marking statistically significant thresholds were included at 0.05 (dashed orange line) and 0.01 FDR value levels (dashed red line).

565

Extended Data Fig. 10. Effects of PM<sub>2.5</sub> exposure in large genomic alterations in LCINS. ab, Differences in the number of CN segments and SV events using univariate comparisons (a) as
well as multivariable linear regressions, considering clinical and epidemiological covariates (b),
including age, sex, genetic ancestry, histology, and tumor purity, for patients diagnosed in
geographical regions with high and low PM<sub>2.5</sub> exposure levels (threshold defined at 20 µg/m<sup>3</sup>; only

samples for which the country of origin was known, n=853, were included). **c**, Volcano plots indicating enrichment of mutational signatures derived from CN and SV alterations. Horizontal lines marking statistically significant thresholds were included at 0.05 (dashed orange line) and 0.01 FDR value levels (dashed red line).

575

576 Extended Data Fig. 11. Assignment of mutational signatures and estimation of telomere 577 length using data from control (n=5) and PM<sub>2.5</sub>-exposed mice (n=5) from Ref.<sup>48</sup>. a-b, Boxplots 578 comparing the mutations assigned to SBS5 (a) and the estimations for the telomere length ratio 579 between the tumor and normal samples (b). Student's t-tests were used to calculate statistical 580 significance.

581

588

Extended Data Fig. 12. Mutagenic effects of PM<sub>2.5</sub> exposure in LCINS cases excluding SBS4 contributions. a, Quantification of SBS burden excluding SBS4 mutations for patients living in geographical regions with high and low PM<sub>2.5</sub> exposure levels (threshold defined at 20  $\mu$ g/m<sup>3</sup>; only samples for which the country of origin was known, *n*=853, were included). **b**, Forest plot corresponding to a multivariable linear regression considering high/low PM<sub>2.5</sub> exposure group, age, sex, genetic ancestry, histology, and tumor sample purity as covariates and SBS burden as

independent variable. c, Scatter plot showing a significant correlation between individual sample

589 estimates of PM<sub>2.5</sub> exposure and SBS burden.

590 SUPPLEMENTARY MATERIAL LEGEN	<b>IDS</b>
----------------------------------	------------

- 591 Supplementary Table 1. Clinical characteristics of the Sherlock-Lung never-smoking lung
- 592 cancer cohort by histology.
- 593
- 594 Supplementary Table 2. Mutational profiles for SBS *de novo* extracted mutational
- 595 signatures using the SBS-288 mutational context.

596

- 597 Supplementary Table 3. Mutational profiles for ID *de novo* extracted mutational signatures
- 598 using the ID-83 mutational context.

599

- 600 Supplementary Table 4. Mutational profiles for DBS *de novo* extracted mutational
- 601 signatures using the DBS-78 mutational context.
- 602
- 603 Supplementary Table 5. Mutational profiles for CN *de novo* extracted mutational
- 604 signatures using the CN-68 mutational context.

605

606 Supplementary Table 6. Mutational profiles for SV *de novo* extracted mutational

607 signatures using the SV-38 mutational context.

608

- 609 Supplementary Table 7. Decomposition of SBS *de novo* mutational signatures into
- 610 COSMICv3.4 reference signatures.

611

612	Supplementary Table 8. Decomposition of ID <i>de novo</i> mutational signatures into
613	COSMICv3.4 reference signatures.
614	
615	Supplementary Table 9. Decomposition of DBS de novo mutational signatures into
616	COSMICv3.4 reference signatures.
617	
618	Supplementary Table 10. Decomposition of CN <i>de novo</i> mutational signatures into
619	COSMICv3.4 reference signatures.
620	
621	Supplementary Table 11. Decomposition of SV <i>de novo</i> mutational signatures into
622	COSMICv3.4 reference signatures.
623	
624	Supplementary Table 12. Associations of passive smoking and pollution with genomic
625	features adjusted by genetic ancestry principal components.
626	
627	Supplementary Table 13. dbGaP and EGA unique identifiers for the publicly available
628	datasets included as part of the analyzed LCINS cohort.
629	
630	Supplementary Fig. 1. De novo mutational signatures extracted using the SBS-288
631	mutational context. a, Mutational profiles of the <i>de novo</i> extracted signatures, with indication of
632	the cosine similarity of the decomposition into COSMICv3.4 reference signatures. <b>b</b> , Contribution
633	of the different COSMICv3.4 reference mutational signatures after decomposition of the de novo
634	extracted signatures. c, Activity of <i>de novo</i> mutational signatures across samples, representing the

total number of substitutions attributed to each signature in a given sample. Dots represent
individual samples, colors different histology types, and purple horizontal bars median values
across all histologies. The numbers on top indicate the total number of samples where a particular
signature was found active (blue) and the total number of samples of the assessed cohort (green).

640 Supplementary Fig. 2. De novo mutational signatures extracted using the ID-83 mutational 641 context. a, Mutational profiles of the *de novo* extracted signatures. b, Contribution of the different 642 COSMICv3.4 reference mutational signatures after decomposition of the de novo extracted 643 signatures. c, Activity of *de novo* mutational signatures across samples, representing the total 644 number of indels attributed to each signature in a given sample. Dots represent individual samples, 645 colors represent different histology types, and purple horizontal bars represent median values 646 across all histologies. The numbers on top indicate the total number of samples where a particular signature was found active (blue) and the total number of samples of the assessed cohort (green). 647

648

649 Supplementary Fig. 3. De novo mutational signatures extracted using the DBS-78 mutational 650 context. a, Mutational profiles of the *de novo* extracted signatures. b, Contribution of the different 651 COSMIC v3.4 reference mutational signatures after decomposition of the *de novo* extracted 652 signatures. c, Activity of *de novo* mutational signatures across samples, representing the total 653 number of doublets attributed to each signature in a given sample. Dots represent individual 654 samples, colors represent different histology types, and purple horizontal bars represent median values across all histologies. The numbers on top indicate the total number of samples where a 655 656 particular signature was found active (blue) and the total number of samples of the assessed cohort 657 (green).

658

Supplementary Fig. 4. De novo mutational signatures extracted using the CN-68 mutational 659 660 context. a. Mutational profiles of the *de novo* extracted signatures. b. Contribution of the different 661 COSMICv3.4 reference mutational signatures after decomposition of the de novo extracted 662 signatures. c, Activity of *de novo* mutational signatures across samples, representing the total 663 number of copy number segments attributed to each signature in a given sample. Dots represent 664 individual samples, colors represent different histology types, and purple horizontal bars represent median values across all histologies. The numbers on top indicate the total number of samples 665 666 where a particular signature was found active (blue) and the total number of samples of the 667 assessed cohort (green).

668

669 Supplementary Fig. 5. De novo mutational signatures extracted using the SV-38 mutational 670 context. a, Mutational profiles of the *de novo* extracted signatures. b, Contribution of the different 671 COSMIC v3.4 reference mutational signatures after decomposition of the *de novo* extracted 672 signatures. c, Activity of *de novo* mutational signatures across samples, representing the total 673 number of structural variants attributed to each signature in a given sample. Dots represent 674 individual samples, colors represent different histology types, and purple horizontal bars represent 675 median values across all histologies. The numbers on top indicate the total number of samples 676 where a particular signature was found active (blue) and the total number of samples of the 677 assessed cohort (green).

678

679 Supplementary Fig. 6. Validation of homologous recombination deficient cases in LCINS

680 using computational predictors. The x-axis shows the probability prediction scores for all the

LCINS cases in the cohort (categorized by histology and presence of signature SBS3) using
HRDetect<sup>31</sup>, whereas the y-axis shows the probability prediction scores for CHORD<sup>30</sup>. Dashed
lines showed the thresholds proposed by both computational tools for considering a sample as
homologous recombination deficient or proficient.
Supplementary Fig. 7. Sensitivity analysis of the associations of mutational signatures with

687 geographical regions excluding Canadian patients with EAS genetic ancestry. Volcano plot

688 indicating enrichment of SBS signatures in patients from East Asian (AS) and North

689 American/European regions (NA/EU) in LCINS adenocarcinomas (top panel) and bar plot

690 indicating prevalence by geographical region (bottom panel). Horizontal lines marking

691 statistically significant thresholds were included at 0.05 (dashed orange line) and 0.01 FDR

692 levels (dashed red line).

693

Supplementary Fig. 8. Passive smoking influence in the genomic landscape of lung adenocarcinomas from never smokers. a-d, Differences in base substitution burden and telomere length ratio between tumor and normal samples using univariate comparisons (a and b) as well as multivariable linear regressions considering clinical and epidemiological covariates (c and d), including age, sex, genetic ancestry, and tumor purity.

699

Supplementary Fig. 9. Assessment of the resolution to assign signature SBS4 in cases exposed
 to secondhand smoke. COSMICv3.4 mutational signatures obtained for the whole cohort of
 LCINS patients were assigned to 247 tumors from SBS4-negative patients exposed to secondhand
 smoke after the synthetic injection of SBS4 at different levels (1%, 2%, 5%, 10%, 15%, and 20%;

710	Supplementary Fig. 10. Split of samples in pollution exposure groups according to their levels
709	
708	represents the contribution level of SBS4 to the overall mutational profile.
707	to a sample, each column to a simulation corresponding to a specific injection level, and the color
706	Detail of the SBS4 contributions observed in the synthetic samples, where each row corresponds
705	samples where SBS4 was detected for different simulations within a synthetic injection level. <b>b</b> ,
704	100 simulations per injection level). a, Boxplots showing the distribution of the proportion of

- 711 of estimated population weighted PM<sub>2.5</sub>. Limit used for the two-group classification (high-low;
- 712  $20 \,\mu g/m^3$ ; 440 high exposed samples vs. 413 low exposed samples).

### 713 ONLINE METHODS

### 714 Ethics declarations

Since the National Cancer Institute only received de-identified samples and data from collaborating centers, had no direct contact or interaction with the study participants, and did not use or generate identifiable private information, Sherlock-*Lung* has been determined to constitute "Not Human Subject Research (NHSR)" based on the federal Common Rule (45 CFR 46; <a href="https://www.ecfr.gov/cgi-bin/ECFR?page=browse">https://www.ecfr.gov/cgi-bin/ECFR?page=browse</a>).

720

### 721 Collection of lung cancer samples

722 Fresh-frozen tumor tissue and matched germline DNA from whole-blood samples or fresh-frozen 723 normal lung tissue sampled approximately 3 cm from the tumor were obtained from 871 treatment-724 naïve lung cancer patients from 14 institutions/centers across the world after sample and 725 sequencing quality control. Among these patients, 114 were from the Institut universitaire de 726 cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-UL), Quebec, Canada; 54 727 from Université Côte d'Azur, Nice, France; 25 from the EAGLE study from Italy<sup>53</sup>; 22 from Yale 728 University, New Haven, Connecticut, USA; 11 from H. Lee Moffitt Cancer Center & Research 729 Institute, Tampa, Florida, USA; 27 from Harvard University, Cambridge, Massachusetts, USA; 730 113 from Hong-Kong; 192 from the International Agency for Research on Cancer, Lyon, France; 731 13 from Mayo Clinic, Rochester, Minnesota, USA; 13 from Roswell Park Comprehensive Cancer 732 Center, Buffalo, New York, USA; 185 from Taipei; 68 from Toronto, Canada; 5 from Valencia, Spain; and 29 from previously published and publicly available whole-genome sequenced (WGS) 733 734 lung cancers from never smokers (Supplementary Table 13). For these 871 individuals, the mean 735 age at lung cancer diagnosis was 64.1 years (range: 21–92) and 79.0% of patients were female.

736

Similar to our prior publication<sup>19</sup>, we utilized seven rigorous criteria for sample inclusion: (i) 737 738 Sequencing coverage. We maintained a minimum average sequencing coverage of >40x for tumor 739 samples and >25x for normal samples; (ii) Contamination and Relatedness. Cross-sample 740 contamination was limited to <1% by Conpair<sup>54</sup>, and detected relatedness was maintained <0.2 by 741 Somalier<sup>55</sup>; (iii) Copy number analysis. Subjects with abnormal copy number profiles in normal samples were excluded, as determined by Battenberg<sup>56</sup>; (iv) Mutational signatures. Tumor samples 742 743 exhibiting mutational signatures SBS7 (associated with ultraviolet light exposure<sup>41</sup>) and SBS31 (associated with platinum chemotherapy<sup>57</sup>) were removed from the analysis. (v) Tumor type 744 745 validation. Tumor samples reported as non-lung cancer or not originating from primary lung cancer were excluded. (vi) WGS quality control. Tumor samples with a total genomic alteration 746 count of <100 or <1000 along with NRPCC (the number of reads per clonal copy)<sup>58</sup> <10 were 747 748 excluded as low-quality samples. (vii) Multiple-region sequencing. In rare cases where multiple 749 regions of a tumor were sequenced, only one high-purity tumor sample was included to avoid 750 redundancy. These stringent criteria were applied consistently to ensure the robustness and 751 reliability of the data collected for the Sherlock-Lung study.

752

All 871 matched tumor and germline samples underwent DNA WGS. Except for the 29 previously generated WGS cancers<sup>18,59-62</sup>, sequencing was performed the same for all other samples. Specifically, frozen tumor tissue with matched blood or normal tissue samples were immediately put into 1ml of 0.2 mg/ml Proteinase K (Qiagen) in DNA lysis buffer (10 mMTris-Cl (pH 8.0), 0.1 M EDTA (pH 8.0), and 0.5% (w/v) SDS) for 24 hours at 56°C with shaking at 850 rpm in Thermomixer R (Eppendorf) until the tissue was completely lysed. Genomic DNA was extracted

759	from fresh frozen tissue using the QIAmp DNA Mini Kit (Qiagen) according to the manufacturer's
760	instructions. Each sample was eluted in 200 $\mu$ l AE buffer and DNA concentration was determined
761	by Nanodrop spectrophotometer. All DNA samples were aliquoted and stored at -80°C until use.
762	
763	DNA was quantified using the QuantiFluor® dsDNA System (Promega Corporation, USA). DNA
764	was normalized to 25ng/ul and underwent fragment analysis via AmpFLSTR™ Identifiler™ PCR
765	Amplification Kit (ThermoFisher Scientific, USA). DNA samples are required to meet minimum
766	mass and concentration thresholds for each assay, as well as show no evidence of contamination
767	or profile discordance in the Identifiler assay. Samples meeting these requirements were aliquoted
768	at the appropriate mass needed for downstream assay processing.
769	
770	Whole-genome sequencing (WGS)
771	The resulting post-capture enriched multiplexed sequencing libraries were used in cluster
772	formation on an Illumina cBOT (Illumina, San Diego, CA, USA). Paired-end sequencing was
773	performed by the Broad Institute (https://www.broadinstitute.org) using the Illumina HiSeq X
774	system following Illumina-provided protocols for 2x151bp paired-end sequencing. FASTQ files

775 were generated after Illumina base-calling. Next, paired FASTQ were converted to unmapped

776 BAM using the GATK pipeline (<u>https://github.com/gatk-workflows/seq-format-conversion</u>). The

vnmapped BAM files were then processed using GATK on the cloud-based platform TERRA

778 workspaces (<u>https://app.terra.bio</u>). The sequence data were aligned to the human reference genome

GRCh38, and the aligned BAM files were transferred to the NIH HPC system (<u>https://hpc.nih.gov</u>)

780 for downstream analyses.

For the public WGS data, the preprocessed aligned BAM/CRAM files (including unmapped reads)
were first converted back to FASTQ files using Bazam (v.1.0.1)<sup>63</sup> to retain the sequencing lane
and read group information and then processed using the same pipeline as for the Sherlock-*Lung*WGS dataset.

786

#### 787 Somatic variant calling

The somatic variant calling was performed using our established bioinformatics pipeline as 788 previously described<sup>19</sup>. The analysis-ready BAM files were processed using four different 789 mutation calling algorithms for tumor-normal paired analysis, including MuTect<sup>64</sup>, MuTect2, 790 Strelka v.2.9.10<sup>65</sup> and TNscope<sup>66</sup>, implemented in the Sentieon's genomics software (v202010.01). 791 We employed an ensemble method to merge the results from these different callers followed by 792 793 additional filtering to reduce false positive calling. The final mutation calls for both single base 794 substitutions (SBSs) and small insertions and deletions (indels) were required to meet the 795 following criteria: (i) read depth >12 in tumor samples and >6 in normal samples; (ii) variant allele 796 frequency <0.02 in the matched-normal sample; and *(iii)* overall allele frequency (AF) <0.001 in 797 multiple genetics databases including 1000 Genomes (phase 3 v5), gnomAD exomes (v2.1.1), and gnomAD genomes (v3.0)<sup>67</sup>. The filtered variants were annotated with Oncotator v.1.9.1.0<sup>68</sup> and 798 799 ANNOVAR v.2019-10-2495. For the indel calling, only variants called by at least three algorithms were kept (MuTect2, Strelka, and TNscope). The UPS-indel<sup>69</sup> algorithm was used to compare and 800 801 combine different indel call sets. Similar filtering steps as those used for SNV calling were also applied to indel calling. The final set of indels were left-normalized (left-aligned and trimmed) for 802 803 the downstream analysis.

# 805 Ancestry estimation

To confirm the genetic ancestry of the patients, we calculated the principal component (PC) coordinates based on WGS data. This analysis was performed using the VerifyBamID (v.2.0.1) algorithm<sup>70</sup> in conjunction with samples from the 1000 Genomes Project<sup>21</sup>.

809

#### 810 Driver gene discovery

The IntOGen pipeline v2020.02.0123<sup>71</sup>, which combines seven state-of-the-art computational 811 812 methods, was employed to detect signals of positive selection in the mutational pattern of driver 813 genes across the cohort. The 65 genes identified as drivers with combination q-value<0.1 in the 814 cohort were classified according to their mode of action in tumorigenesis (*i.e.*, tumor suppressor 815 genes or oncogenes) based on the relationship between the excess of observed nonsynonymous and truncating mutations computed by dNdScv<sup>72</sup> and their annotations in the Cancer Gene 816 817 Census<sup>73</sup>. Genes with conflicting computed and annotated modes of action were labeled 818 ambiguous. To identify potential driver mutations across the 65 cancer driver genes annotated in 819 the Cancer Gene Census, we selected mutations that fulfilled any of the following criteria: (i) truncating mutations in genes annotated as tumor suppressors; (ii) recurrent missense mutations 820 (seen in at least three independent tumors); (iii) mutations classified as "Likely Drivers" by 821 boostDM (score >0.5)74; (iv) mutations classified as "Oncogenic" or "Likely Oncogenic" by 822 OncoKB<sup>75</sup>; (v) mutations classified as drivers in the TCGA MC3 drivers study<sup>76</sup>; (vi) missense 823 mutations classified as "Likely Pathogenic" by AlphaMissense<sup>77</sup> in genes annotated as tumor 824 825 suppressors.

826

### 827 Estimation of tumor purity, ploidy, and allele-specific copy numbers

We used the Battenberg algorithm (v2.2.9)56 to conduct analyses of somatic copy number 828 829 alterations (SCNA). Initial SCNA profiles were generated, followed by an assessment of the 830 clonality of each segment, purity, and ploidy. Any SCNA profile determined to have low-quality 831 after manual inspection underwent a refitting process using the Battenberg algorithm. This process required new tumor purity and ploidy inputs, either estimated by ccube  $(v1.0)^{78}$  or recalculated 832 from local copy number status. The Battenberg refitting procedures were iteratively executed until 833 the final SCNA profile was established and met the criteria of manual validation check. GISTIC 834 (v2.0)<sup>79</sup> was used to identify the recurrent copy number alterations at the gene level based on the 835 836 major clonal copy number for each segmentation.

837

### 838 Structural variants calling

Meerkat (v.0.189)<sup>80</sup> and Manta (v.1.6.0)<sup>81</sup> were applied with recommended filtering for identifying
structural variants (SVs), and the union set of these two callers was merged as the final SV dataset.

### 842 **Telomere length**

We estimated telomere length in kb using TelSeq  $(v.0.0.2)^{82}$  for all 871 LCINS samples as well as mouse data from a recent experimental study, including control and PM<sub>2.5</sub>-exposed mice<sup>48</sup>. We used seven as the threshold for the number of TTAGGG/CCCTAA repeats in a read for the read to be considered telomeric. The TelSeq calculation was done individually for each read group within a sample, and the total number of reads in each read group was used as weight to calculate the average TL for each sample.

849

#### 851 Mutational signature analysis

# 852 *Extraction of de novo mutational signatures*

853 De novo mutational signatures for single base substitutions (SBS), doublet base substitutions 854 (DBS), and indels (ID) were extracted using SigProfilerExtractor<sup>22</sup> v1.1.21 with default parameters and normalization set to 10,000 mutations, in order to limit the effect of hypermutators in the 855 856 signature extraction process. For SBSs, de novo signatures were extracted using the SBS-288 and SBS-1536 high-definition mutational contexts, which, beyond the common SBS-96 trinucleotide 857 858 context using the mutated base and the 5' and 3' adjacent nucleotides<sup>83,84</sup>, also consider the 859 transcriptional strand bias and the pentanucleotide context (two 5' and 3' adjacent nucleotides), respectively<sup>84</sup>. Given the high similarity obtained for both mutational contexts as well as the 860 861 additional separation of mutational processes obtained by the SBS-288 mutational context (11 de 862 novo signatures using SBS-288 vs. 10 de novo signatures using SBS-1536; average cosine similarity 0.97), the results using the SBS-288 context were used for further analysis 863 (Supplementary Table 2). Previously established mutational contexts DBS-78 and ID-83<sup>15,84</sup> 864 865 were used for the extraction of DBS and ID signatures (Supplementary Tables 3-4). Copy number 866 signatures were extracted *de novo* following an updated context definition benefitting from deep 867 WGS data (CN-68) (Supplementary Table 5), which allowed to further characterize CN segments below 100kbp in length (in contrast to current COSMICv3.4 reference signatures using the CN-48 868 869 context, which are based on SNP6 microarray data and therefore without the resolution to characterize short CN segments)<sup>26</sup>. SV signatures were extracted using a similarly refined context, 870 871 with an in-depth characterization of short SV alterations below 1kbp (SV-38 context; 872 Supplementary Table 6).

#### 874 Decomposition and assignment of mutational signatures to individual tumors

After *de novo* extraction was completed, SigProfilerAssignment<sup>85</sup> v0.1.1 was used to decompose 875 876 the *de novo* extracted SBS, ID, DBS, CN, and SV mutational signatures into COSMICv3.4<sup>23</sup> 877 reference signatures based on the GRCh38 reference genome (Supplementary Tables 7-11) as 878 well as to assign signatures to individual samples obtaining signature activities, based on the 879 forward stagewise algorithm for sparse regression and nonnegative least squares for numerical 880 optimization. Hierarchical clustering of the activities of mutational signatures was performed using Euclidean distance and Ward's minimum-variance clustering. For the SBS signatures, the 11 de 881 882 novo extracted signatures were originally decomposed into 15 COSMICv3.4 reference signatures. 883 However, two of the COSMICv3.4 signatures, enriched in C>T substitutions, were removed from 884 the decomposition to avoid misassignment, namely SBS23 and SBS32, as the patterns of strong transcriptional strand bias generated by these two signatures<sup>15</sup> were not observed in our LCINS 885 886 dataset, and their individual contribution to the decomposition of *de novo* signatures was minimal. 887 On the other hand, five additional COSMICv3.4 SBS signatures were included for the assignment 888 to individual samples, including SBS3, SBS21, SBS33, SBS44, and SBS92. SBS3 and SBS92 889 were included considering their previously reported strong associations with indel signatures ID6 890 and ID3, both of which were observed in our indel signature analysis after decomposition to 891 COSMICv3.4 ID signatures<sup>15,22,43</sup>. Thus, for those tumors harboring ID6 (n=41), we allowed 892 assigning SBS3 (assigned only to 14 of the cases), whereas for those tumors with presence of ID3 893 (n=300), SBS92 was allowed in the assignment (assigned to 6 tumors). Suspected homologous recombination deficient (HRD) tumors exhibiting signatures SBS3 and ID6 were tested using two 894 independent computational algorithms, CHORD<sup>30</sup> and HRDetect<sup>31</sup>. Lastly, two samples showing 895 896 a low cosine similarity for the mutational profile reconstruction (NSLC-0477 and NSLC-0637)

897 showed high similarities in their mutational profiles with signatures linked to microsatellite 898 instability (MSI) and COSMIC SBS33, respectively. Considering this, we allowed assignment of 899 SBS33 and all MSI-associated signatures (SBS6, SBS14, SBS15, SBS20, SBS21, SBS26, and 900 SBS44), respectively, in each of this specific samples, with SBS21 and SBS44 being finally assigned to sample NSLC-0477. The MSI phenotype of this sample was independently confirmed 901 by MMRDetect<sup>25</sup>, and further evidence was collected by exploring the indel landscape, with 902 903 10,474 alterations, 29-fold more than the average number of indels in lung adenocarcinomas, and 904 a strong enrichment of signature ID2, consistent with previously reported MSI cases<sup>15</sup>. The 905 decomposed COSMICv3.4 SBS signatures obtained in the whole LCINS cohort were used for the assignment of signatures to the mouse data obtained from a recent publication<sup>48</sup>, after their 906 907 renormalization to the mouse genome (mm10 build).

908

# 909 Assignment of mutational signatures to individual somatic mutations

910 Signatures were probabilistically assigned to individual somatic mutations using 911 SigProfilerAssignment based on Bayes' rule and the specific mutational context for the mutation, as previously described<sup>85</sup>. Briefly, to calculate the probability of a specific mutational signature 912 913 being responsible for a mutation in a given mutational context and in a particular sample, we 914 multiplied the general probability of the signature causing mutations in a specific mutational 915 context (obtained from the mutational signature profile) by the activity of the signature in the 916 sample (obtained from the signature activities), and then normalized this value dividing by the 917 total number of mutations corresponding to the specific mutational context (obtained from the 918 reconstructed mutational profile of the sample).

### 920 Assessment of statistical power to assign mutational signatures in passive smokers

921 To assess the statistical power to assign SBS4 in passive smokers, we performed simulations where 922 SBS4 was injected at different average levels (1%, 2%, 5%, 10%, 15%, and 20% of total mutations 923 in each sample; 100 simulations for each injection level) in all 247 tumors from passive smoker 924 patients lacking SBS4. For each sample, prior to the injection of SBS4, the number of mutations 925 to be injected into the sample was randomly subtracted from the sample while ensuring all 926 mutation counts were still non-negative. Next, SBS4 mutations were injected at the current level 927 being tested. After, 10% Gaussian noise was added to the resulting mutational profile. 928 Subsequently, mutational signatures re-assigned in each sample were using SigProfilerAssignment<sup>85</sup> as well as the 18 SBS COSMICv3.4 reference signatures considered for 929 the original data using default parameters except for a relaxed addition penalty 930 931 (nnls add penalty=0.01) in order to increase the sensitivity of the signature assignment analysis.

932

## 933 Evaluating the topography of mutational signatures

934 Topography analyses specific for the 56 SBS4 positive samples as well as 68 lung cancer 935 samples from smoker patients from the Pan-Cancer Analysis of Whole Genomes (PCAWG) cohort<sup>45</sup> were carried out with SigProfilerTopography<sup>86</sup>, which evaluates the effect of DNA 936 937 replication, DNA transcription, chromatin organization, histone modifications, and transcription 938 factor binding on the activities of different mutational processes. SigProfilerTopography 939 examines the distribution of topographical features and narrows down the analyses by calculating 940 the average signal of each feature in the close vicinity of the somatic mutations. Next, all the 941 results of somatic mutations are statistically compared with those from simulated mutations that

account for the patterns of all operative mutational signatures within an examined sample toelucidate statistically significant differences.

### 944 Estimating air pollution

945 Annual country-level population-weighted mean concentration estimates of the environmental particulate matter measuring  $\leq 2.5 \,\mu m \, (PM_{2.5}) \, (\mu g/m^3)$  from 1998–2021 were obtained from a 946 947 hybrid model combining measurements of aerosol optical depth from different satellites (MODIS, VIIRS, MISR, and SeaWiFS) with chemical transport modeling (GEOS-Chem) and ground-based 948 observations<sup>49</sup>, 949 photometer (AERONET) and downloaded from 950 https://sites.wustl.edu/acag/datasets/surface-pm2-5/. Additional state-level and provincial-level 951 yearly mean estimates were also used for the patients from the United States and Canada, respectively. An individual estimate of the PM<sub>2.5</sub> exposure for each patient was calculated by 952 953 averaging the annual mean concentration values from the year of lung cancer diagnosis (calculated by adding the age of diagnosis to the year of birth) until the earliest year with data available, i.e., 954 955 1998. For two patients diagnosed before 1998, as well as for 28 patients whose age of diagnosis 956 or year of birth was unknown, the PM<sub>2.5</sub> estimates for 1998 were considered. PM<sub>2.5</sub> estimates were 957 not available for 18 cases for which the country of residence was unknown. For the dichotomized 958 analysis between high and low polluted regions according to the levels of individual estimates of the PM<sub>2.5</sub> exposure, a threshold of 20  $\mu$ g/m<sup>3</sup> was used, considering the distribution of PM<sub>2.5</sub> 959 960 estimates across the whole cohort (Supplementary Fig. 10).

961

962 Association of geographical regions, histologies, EGFR driver mutation status, air

963 pollution, and passive smoking with genomic features

964 In order to quantify the influence of passive smoking and air pollution on the number of total somatic mutations and the ratio of telomere length between tumor and normal samples, we fitted 965 a series of multivariable linear models, including adjustments for several confounding covariates, 966 967 namely age, sex, genetic ancestry, histology, and tumor purity. The total number of mutations 968  $(\log_{10} \text{ scale})$  or telomere length ratio  $(\log_2 \text{ scale})$  served as dependent variables for the linear 969 regressions, respectively, whereas passive smoking/air pollution groups and covariates were used 970 as independent variables. In addition, for assessing the dose-response effect of air pollution, we 971 fitted multivariable linear regressions using the individual  $PM_{2.5}$  estimates per sample, considering 972 similar adjustments as in the analysis by pollution groups. Genetic ancestry was primarily 973 considered for the adjustments based on the super-samples from the 1,000 Genomes Project<sup>21</sup>, 974 classifying the samples into EUR, EAS, or Other genetic ancestry (Fig. 1b). Additionally, we also 975 considered the genetic ancestry principal components derived from the WGS data for the 976 adjustments, with no differences in the associations compared to the ancestry label-based 977 adjustments (Supplementary Table 12)

978

979 Similarly, the presence of specific mutational signatures or mutations in specific driver genes was 980 modeled based on the influence of geographical region/histology/EGFR mutation status/passive 981 smoking/air pollution and the additional covariates previously considered, including age, sex, genetic ancestry, tumor purity, and histology (if applicable), by using multivariable logistic 982 983 regressions. For this purpose, signature activities were dichotomized into the presence or absence 984 of a particular signature, and these binary activities served as dependent variables for the logistic 985 regressions, with geographical regions, EGFR mutation status, histology subtypes, passive 986 smoking groups, or individual PM<sub>2.5</sub> estimates, respectively, along with covariates, being used as

987 independent variables. For signatures present in more than 50% of the cases, dichotomization was 988 done above and below the median of assigned mutations to the overall cohort of LCINS patients 989 (n=871). Signatures SBS21, SBS33, and SBS44 were excluded from the analysis as they were only 990 found in individual tumors. For the enrichment analysis of mutations in driver genes, the presence 991 or absence of mutations in specific genes was used as the dependent variable for the logistic 992 regressions. Only driver genes having driver mutations in more than 2% of cases of the assessed 993 cohort were considered.

994

995 In addition, to assess the dose-response effect of air pollution, we fitted multivariable linear 996 regressions using the individual PM<sub>2.5</sub> estimates per sample, considering similar corrections for 997 covariates and the tumor mutational burden ( $\log_{10}$  scale), the telomere length ratio ( $\log_2$  scale), or 998 the number of mutations contributed by a given signature ( $log_{10}$  scale) as the dependent variable. 999 Only samples where a particular mutational signature was present were considered for the 1000 multivariable linear regressions. Univariate linear regressions for the average tumor mutational 1001 burden ( $\log_{10}$  scale), the telomere length ratio ( $\log_2$  scale), or the number of mutations contributed 1002 by a given signature ( $\log_{10}$  scale) vs. the average PM<sub>2.5</sub> per geographical region were used for 1003 visualization.

1004

In all cases, p-values were corrected according to the different signatures from the same variant
 type or driver genes considered by using a false-discovery rate correction based on the Benjamini Hochberg method<sup>87</sup> and reported as FDR. FDR<0.05 were considered statistically significant.</li>

1008

1009 Statistical analysis

All statistical analyses and graphic displays were performed using the R software v4.2.3 (https://www.r-project.org/). Two-sided Fisher's exact tests were used for the enrichment analyses of categorical variables. For the comparison of numerical variables across groups, we used nonparametric Mann-Whitney (Wilcoxon rank sum) tests. P-values<0.05 were considered statistically significant. If multiple hypothesis testing was required, we used a false-discovery rate correction based on the Benjamini-Hochberg method<sup>87</sup> and reported FDR. FDR<0.05 were considered statistically significant.

1017

# 1018 DATA AVAILABILITY

1019 Normal and tumor-paired CRAM files for the 871 WGS subjects of the Sherlock-*Lung* study have
1020 been deposited in dbGaP under the accession numbers phs001697.v1.p1. Detailed access
1021 information for the publicly available datasets can be found in Supplementary Table 13.

1022

## **1023 CODE AVAILABILITY**

1024 The WGS bioinformatics pipelines can be accessed at <u>https://github.com/xtmgah/Sherlock-Lung</u>.
1025 Battenberg SCNA calling algorithm can be found at <u>https://github.com/Wedge-lab/battenberg</u>.
1026

### **1027 ACKNOWLEDGEMENTS**

This work was supported by the Intramural Research Program of the National Cancer Institute, US 1028 National Institute of Health (NIH) (project ZIACP101231 to MTL); by the NIH grants 1029 R01ES032547-01, R01CA269919-01, and 1U01CA290479-01 to LBA as well as by LBA's 1030 Packard Fellowship for Science and Engineering. The research performed in LBA's lab was also 1031 1032 supported by UC San Diego Sanford Stem Cell Institute. The funders had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The 1033 computational analyses reported in this manuscript have utilized the Triton Shared Computing 1034 1035 Cluster at the San Diego Supercomputer Center of UC San Diego. We thank the study participants, 1036 Dr. Peter Kraft for his reviewing of the manuscript and insightful comments, and the staff at Westat 1037 Inc. for their valuable assistance in collecting samples and corresponding clinical data. This work utilized the computational resources of the NIH high-performance computational capabilities 1038 Biowulf cluster (http://hpc.nih.gov). 1039

1040

#### **1041 COMPETING INTERESTS**

LBA is a co-founder, CSO, scientific advisory member, and consultant for io9, has equity and 1042 1043 receives income. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. LBA is also 1044 1045 a compensated member of the scientific advisory board of Inocras. LBA's spouse is an employee 1046 of Biotheranostics. ENB and LBA declare U.S. provisional patent application filed with UCSD with serial numbers 63/269,033. LBA also declares U.S. provisional applications filed with UCSD 1047 1048 with serial numbers: 63/366,392; 63/289,601; 63/483,237; 63/412,835; and 63/492,348. LBA is 1049 also an inventor of a US Patent 10,776,718 for source identification by non-negative matrix

- 1050 factorization. SRY has received consulting fees from AstraZeneca, Sanofi, Amgen, AbbVie, and
- 1051 Sanofi; received speaking fees from AstraZeneca, Medscape, PRIME Education, and Medical
- 1052 Learning Institute. All other authors declare that they have no competing interests.

# **1053 REFERENCES**

1054 Proctor, R. N. Tobacco and the global lung cancer epidemic. *Nature Reviews Cancer* 1, 1 1055 82-86 (2001). https://doi.org/10.1038/35094091 Sun, S., Schiller, J. H. & Gazdar, A. F. Lung cancer in never smokers — a different 1056 2 disease. Nature Reviews Cancer 7, 778-790 (2007). https://doi.org/10.1038/nrc2190 1057 1058 3 Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and 1059 Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71, 209-249 (2021). https://doi.org/10.3322/caac.21660 1060 1061 4 Siegel, D. A., Fedewa, S. A., Henley, S. J., Pollack, L. A. & Jemal, A. Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States. JAMA Oncol 1062 7, 302-304 (2021). https://doi.org/10.1001/jamaoncol.2020.6362 1063 5 Lui, N. S. et al. Sub-solid lung adenocarcinoma in Asian versus Caucasian patients: 1064 different biology but similar outcomes. J Thorac Dis 12, 2161-2171 (2020). 1065 https://doi.org/10.21037/jtd.2020.04.37 1066 1067 6 Gaughan, E. M., Cryer, S. K., Yeap, B. Y., Jackman, D. M. & Costa, D. B. Family history of lung cancer in never smokers with non-small-cell lung cancer and its 1068 association with tumors harboring EGFR mutations. Lung Cancer 79, 193-197 (2013). 1069 1070 https://doi.org/10.1016/j.lungcan.2012.12.002 Toh, C. K. et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct 1071 7 disease entity. J Clin Oncol 24, 2245-2251 (2006). 1072 1073 https://doi.org/10.1200/JCO.2005.04.8033 1074 8 Yano, T. et al. Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer 113, 1012-1018 (2008). 1075 https://doi.org/10.1002/cncr.23679 1076 9 Brennan, P. et al. High cumulative risk of lung cancer death among smokers and 1077 nonsmokers in Central and Eastern Europe. Am J Epidemiol 164, 1233-1241 (2006). 1078 1079 https://doi.org/10.1093/aje/kwj340 1080 10 Wang, P., Sun, S., Lam, S. & Lockwood, W. W. New insights into the biology and development of lung cancer in never smokers-implications for early detection and 1081 treatment. J Transl Med 21, 585 (2023). https://doi.org/10.1186/s12967-023-04430-x 1082 1083 11 Tobacco Smoke and Involuntary Smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 83 1-1438 (2004). 1084 Turner, M. C. et al. Outdoor air pollution and cancer: An overview of the current 1085 12 evidence and public health recommendations. CA Cancer J Clin 70, 460-479 (2020). 1086 https://doi.org/10.3322/caac.21632 1087 Ciabattini, M., Rizzello, E., Lucaroni, F., Palombi, L. & Boffetta, P. Systematic review 13 1088 1089 and meta-analysis of recent high-quality studies on exposure to particulate matter and risk 1090 of lung cancer. Environ Res 196, 110440 (2021). https://doi.org/10.1016/j.envres.2020.110440 1091 Koh, G., Degasperi, A., Zou, X., Momen, S. & Nik-Zainal, S. Mutational signatures: 1092 14 emerging concepts, caveats and clinical applications. Nat Rev Cancer 21, 619-637 1093 (2021). https://doi.org/10.1038/s41568-021-00377-7 1094 15 Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 1095 1096 578, 94-101 (2020). https://doi.org/10.1038/s41586-020-1943-3

- 109716ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, T. Pan-cancer1098analysis of whole genomes. Nature 578, 82-93 (2020). <a href="https://doi.org/10.1038/s41586-020-1969-6">https://doi.org/10.1038/s41586-020-1969-6</a>
- Wang, X. *et al.* Association between Smoking History and Tumor Mutation Burden in
   Advanced Non-Small Cell Lung Cancer. *Cancer Res* 81, 2566-2573 (2021).
   <u>https://doi.org/10.1158/0008-5472.CAN-20-3991</u>
- 1103 18 Lee, J. J. *et al.* Tracing Oncogene Rearrangements in the Mutational History of Lung
  1104 Adenocarcinoma. *Cell* 177, 1842-1857 e1821 (2019).
  1105 https://doi.org/10.1016/j.cell.2019.05.013
- 1106 19 Zhang, T. *et al.* Genomic and evolutionary classification of lung cancer in never smokers.
   1107 Nature Genetics 53, 1348-1359 (2021). https://doi.org/10.1038/s41588-021-00920-0
- Landi, M. T. *et al.* Tracing Lung Cancer Risk Factors Through Mutational Signatures in
  Never-Smokers : The Sherlock-Lung Study. *American Journal of Epidemiology* 190,
  962-976 (2020). https://doi.org/10.1093/aje/kwaa234
- 111121Auton, A. et al. A global reference for human genetic variation. Nature 526, 68-741112(2015). <a href="https://doi.org/10.1038/nature15393">https://doi.org/10.1038/nature15393</a>
- 1113 22 Islam, S. M. A. *et al.* Uncovering novel mutational signatures by de novo extraction with
  1114 SigProfilerExtractor. *Cell Genom* 2, 100179 (2022).
  1115 https://doi.org/10.1016/j.xgen.2022.100179
- 111623Sondka, Z. et al. COSMIC: a curated database of somatic variants and clinical data for1117cancer. Nucleic Acids Res 52, D1210-D1217 (2024). <a href="https://doi.org/10.1093/nar/gkad986">https://doi.org/10.1093/nar/gkad986</a>
- 111824Senkin, S. *et al.* Geographic variation of mutagenic exposures in kidney cancer genomes.1119Nature (2024). <a href="https://doi.org/10.1038/s41586-024-07368-2">https://doi.org/10.1038/s41586-024-07368-2</a>
- 1120 25 Zou, X. *et al.* A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage. *Nature Cancer* 2, 643-657 (2021). <u>https://doi.org/10.1038/s43018-021-00200-0</u>
- 1123
   26
   Steele, C. D. *et al.* Signatures of copy number alterations in human cancer. *Nature* 606, 984-991 (2022). <a href="https://doi.org/10.1038/s41586-022-04738-6">https://doi.org/10.1038/s41586-022-04738-6</a>
- Everall, A. *et al.* Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types from 10,983 cancer patients. *medRxiv*,
- 1127
   2023.2006.2007.23290970 (2023). <a href="https://doi.org/10.1101/2023.06.07.23290970">https://doi.org/10.1101/2023.06.07.23290970</a>

   1128
   28
   Nik-Zainal, S. *et al.* Landscape of somatic mutations in 560 breast cancer whole-genome
- 1129 sequences. *Nature* **534**, 47-54 (2016). <u>https://doi.org/10.1038/nature17676</u>
- 113029Degasperi, A. *et al.* A practical framework and online tool for mutational signature1131analyses show inter-tissue variation and driver dependencies. *Nat Cancer* 1, 249-2631132(2020). <a href="https://doi.org/10.1038/s43018-020-0027-5">https://doi.org/10.1038/s43018-020-0027-5</a>
- Nguyen, L., W. M. Martens, J., Van Hoeck, A. & Cuppen, E. Pan-cancer landscape of homologous recombination deficiency. *Nature Communications* 11, 5584 (2020).
  https://doi.org/10.1038/s41467-020-19406-4
- 1136 31 Davies, H. *et al.* HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on 1137 mutational signatures. *Nat Med* 23, 517-525 (2017). <u>https://doi.org/10.1038/nm.4292</u>
- 113832Poon, S. L. *et al.* Genome-wide mutational signatures of aristolochic acid and its1139application as a screening tool. *Sci Transl Med* 5, 197ra101 (2013).1140https://doi.org/10.1126/scitranslmed.3006086
- 52

1141	33	Hoang, M. L. et al. Mutational signature of aristolochic acid exposure as revealed by
1142		whole-exome sequencing. Sci Transl Med 5, 197ra102 (2013).
1143		https://doi.org/10.1126/scitranslmed.3006200
1144	34	Letouze, E. et al. Mutational signatures reveal the dynamic interplay of risk factors and
1145		cellular processes during liver tumorigenesis. Nat Commun 8, 1315 (2017).
1146		https://doi.org/10.1038/s41467-017-01358-x
1147	35	Chen, YJ. et al. Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates
1148		Molecular Signatures of Pathogenesis and Progression. Cell 182, 226-244.e217 (2020).
1149		https://doi.org/10.1016/j.cell.2020.06.012
1150	36	Zhang, T. et al. APOBEC shapes tumor evolution and age at onset of lung cancer in
1151		smokers. <i>bioRxiv</i> , 2024.2004.2002.587805 (2024).
1152		https://doi.org/10.1101/2024.04.02.587805
1153	37	Morton, L. M. et al. Radiation-related genomic profile of papillary thyroid carcinoma
1154		after the Chernobyl accident. Science 372, eabg2538 (2021).
1155		https://doi.org/10.1126/science.abg2538
1156	38	Jager, M. et al. Deficiency of nucleotide excision repair is associated with mutational
1157		signature observed in cancer. Genome Res 29, 1067-1077 (2019).
1158		https://doi.org/10.1101/gr.246223.118
1159	39	Singh, V. K., Rastogi, A., Hu, X., Wang, Y. & De, S. Mutational signature SBS8
1160		predominantly arises due to late replication errors in cancer. Commun Biol 3, 421 (2020).
1161		https://doi.org/10.1038/s42003-020-01119-5
1162	40	Caplin, M. E. et al. Pulmonary neuroendocrine (carcinoid) tumors: European
1163		Neuroendocrine Tumor Society expert consensus and recommendations for best practice
1164		for typical and atypical pulmonary carcinoids. Ann Oncol 26, 1604-1620 (2015).
1165		https://doi.org/10.1093/annonc/mdv041
1166	41	Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500,
1167		415-421 (2013). https://doi.org/10.1038/nature12477
1168	42	Lindeman, N. I. et al. Molecular testing guideline for selection of lung cancer patients for
1169		EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American
1170		Pathologists, International Association for the Study of Lung Cancer, and Association for
1171		Molecular Pathology. J Thorac Oncol 8, 823-859 (2013).
1172		https://doi.org/10.1097/JTO.0b013e318290868f
1173	43	Lawson, A. R. J. et al. Extensive heterogeneity in somatic mutation and selection in the
1174		human bladder. Science 370, 75-82 (2020). https://doi.org/10.1126/science.aba8347
1175	44	Degasperi, A. et al. Substitution mutational signatures in whole-genome-sequenced
1176		cancers in the UK population. Science 376, ab19283 (2022).
1177		https://doi.org/10.1126/science.ab19283
1178	45	Otlu, B. et al. Topography of mutational signatures in human cancer. Cell Rep 42,
1179		112930 (2023). https://doi.org/10.1016/j.celrep.2023.112930
1180	46	Jamal-Hanjani, M. et al. Tracking the Evolution of Non–Small-Cell Lung Cancer. New
1181		England Journal of Medicine <b>376</b> , 2109-2121 (2017).
1182		https://doi.org/10.1056/NEJMoa1616288
1183	47	Zhang, T. et al. Distinct Genomic Landscape of Lung Adenocarcinoma from Household
1184		Use of Smoky Coal. American Journal of Respiratory and Critical Care Medicine 208,
1185		733-736 (2023). <u>https://doi.org/10.1164/rccm.202302-0340LE</u>

1186	48	Hill, W. <i>et al.</i> Lung adenocarcinoma promotion by air pollutants. <i>Nature</i> <b>616</b> , 159-167
1187	40	(2023). <u>https://doi.org/10.1038/s41586-023-05874-3</u>
1188	49	van Donkelaar, A. et al. Monthly Global Estimates of Fine Particulate Matter and Their
1189		Uncertainty. Environmental Science & Technology 55, 15287-15300 (2021).
1190		<u>https://doi.org/10.1021/acs.est.1c05309</u>
1191	50	Mochizuki, A. et al. Passive smoking-induced mutagenesis as a promoter of lung
1192		carcinogenesis. J Thorac Oncol, S1556-0864(1524)00074-00071 (2024).
1193		https://doi.org/10.1016/j.jtho.2024.02.006
1194	51	Yu, X. J. et al. Characterization of Somatic Mutations in Air Pollution-Related Lung
1195		Cancer. EBioMedicine 2, 583-590 (2015). https://doi.org/10.1016/j.ebiom.2015.04.003
1196	52	Chan, WH. et al. Verifying the accuracy of self-reported smoking behavior in female
1197		volunteer soldiers. Scientific Reports 13, 3438 (2023). https://doi.org/10.1038/s41598-
1198		023-29699-2
1199	53	Landi, M. T. et al. Environment And Genetics in Lung cancer Etiology (EAGLE) study:
1200		an integrative population-based case-control study of lung cancer. BMC Public Health 8,
1201		203 (2008). https://doi.org/10.1186/1471-2458-8-203
1202	54	Bergmann, E. A., Chen, B. J., Arora, K., Vacic, V. & Zody, M. C. Conpair: concordance
1203		and contamination estimator for matched tumor-normal pairs. <i>Bioinformatics</i> <b>32</b> , 3196-
1204		3198 (2016). https://doi.org/10.1093/bioinformatics/btw389
1205	55	Pedersen, B. S. <i>et al.</i> Somalier: rapid relatedness estimation for cancer and germline
1206	00	studies using efficient genome sketches. <i>Genome Medicine</i> <b>12</b> , 62 (2020).
1200		https://doi.org/10.1186/s13073-020-00761-2
1207	56	Nik-Zainal, S. <i>et al.</i> The life history of 21 breast cancers. <i>Cell</i> <b>149</b> , 994-1007 (2012).
1200	50	https://doi.org/10.1016/j.cell.2012.04.023
1209	57	Boot, A. <i>et al.</i> In-depth characterization of the cisplatin mutational signature in human
1210	57	cell lines and in esophageal and liver tumors. <i>Genome Res</i> 28, 654-665 (2018).
1211		https://doi.org/10.1101/gr.230219.117
1212	58	Dentro, S. C. <i>et al.</i> Characterizing genetic intra-tumor heterogeneity across 2,658 human
	30	cancer genomes. <i>Cell</i> <b>184</b> , 2239-2254 (2021). https://doi.org/10.1016/j.cell.2021.03.009
1214	59	
1215	39	Imielinski, M. <i>et al.</i> Mapping the hallmarks of lung adenocarcinoma with massively
1216		parallel sequencing. <i>Cell</i> <b>150</b> , 1107-1120 (2012).
1217	(0)	https://doi.org/10.1016/j.cell.2012.08.029
1218	60	Lee, J. K. <i>et al.</i> Clonal History and Genetic Predictors of Transformation Into Small-Cell
1219		Carcinomas From Lung Adenocarcinomas. J Clin Oncol 35, 3065-3074 (2017).
1220		https://doi.org/10.1200/JCO.2016.71.9096
1221	61	Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung
1222		adenocarcinoma. Nature 511, 543-550 (2014). https://doi.org/10.1038/nature13385
1223	62	Carrot-Zhang, J. et al. Whole-genome characterization of lung adenocarcinomas lacking
1224		the RTK/RAS/RAF pathway. Cell Rep 34, 108707 (2021).
1225		https://doi.org/10.1016/j.celrep.2021.108707
1226	63	Sadedin, S. P. & Oshlack, A. Bazam: a rapid method for read extraction and realignment
1227		of high-throughput sequencing data. Genome Biol 20, 78 (2019).
1228		https://doi.org/10.1186/s13059-019-1688-1
1229	64	Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and
1230		heterogeneous cancer samples. Nat Biotechnol <b>31</b> , 213-219 (2013).
1231		https://doi.org/10.1038/nbt.2514

Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat

1232

65

1233 Methods 15, 591-594 (2018). https://doi.org/10.1038/s41592-018-0051-x 1234 Freed, D., Pan, R. & Aldana, R. TNscope: Accurate Detection of Somatic Mutations with 66 1235 Haplotype-based Variant Candidate Detection and Machine Learning Filtering. *bioRxiv*, 250647 (2018). https://doi.org/10.1101/250647 1236 1237 67 Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 1238 141,456 humans. Nature 581, 434-443 (2020). https://doi.org/10.1038/s41586-020-2308-1239 7 1240 68 Ramos, A. H. et al. Oncotator: cancer variant annotation tool. Hum Mutat 36, E2423-1241 2429 (2015). https://doi.org/10.1002/humu.22771 Hasan, M. S., Wu, X., Watson, L. T. & Zhang, L. UPS-indel: a Universal Positioning 1242 69 1243 System for Indels. Sci Rep 7, 14106 (2017). https://doi.org/10.1038/s41598-017-14400-1 70 Jun, G. et al. Detecting and estimating contamination of human DNA samples in 1244 sequencing and array-based genotype data. Am J Hum Genet 91, 839-848 (2012). 1245 https://doi.org/10.1016/j.ajhg.2012.09.004 1246 1247 71 Martinez-Jimenez, F. et al. A compendium of mutational cancer driver genes. Nat Rev Cancer 20, 555-572 (2020). https://doi.org/10.1038/s41568-020-0290-x 1248 Martincorena, I. et al. Universal Patterns of Selection in Cancer and Somatic Tissues. 1249 72 Cell 171, 1029-1041 (2017). https://doi.org/10.1016/j.cell.2017.09.042 1250 Sondka, Z. et al. The COSMIC Cancer Gene Census: describing genetic dysfunction 1251 73 across all human cancers. Nat Rev Cancer 18, 696-705 (2018). 1252 1253 https://doi.org/10.1038/s41568-018-0060-1 1254 74 Muiños, F., Martinez-Jimenez, F., Pich, O., Gonzalez-Perez, A. & Lopez-Bigas, N. In silico saturation mutagenesis of cancer genes. Nature 596, 428-432 (2021). 1255 https://doi.org/10.1038/s41586-021-03771-1 1256 Chakravarty, D. et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis 1257 75 Oncol 2017, 1-16 (2017). https://doi.org/10.1200/PO.17.00011 1258 Bailey, M. H. et al. Comprehensive Characterization of Cancer Driver Genes and 1259 76 1260 Mutations. Cell 173, 371-385 e318 (2018). https://doi.org/10.1016/j.cell.2018.02.060 77 Cheng, J. et al. Accurate proteome-wide missense variant effect prediction with 1261 AlphaMissense. Science 381, eadg7492 (2023). https://doi.org/10.1126/science.adg7492 1262 Yuan, K., Macintyre, G., Liu, W. & Markowetz, F. Ccube: A fast and robust method for 1263 78 estimating cancer cell fractions. bioRxiv, 484402 (2018). https://doi.org/10.1101/484402 1264 79 Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the 1265 targets of focal somatic copy-number alteration in human cancers. Genome Biol 12, R41 1266 (2011). https://doi.org/10.1186/gb-2011-12-4-r41 1267 Yang, L. et al. Diverse mechanisms of somatic structural variations in human cancer 1268 80 1269 genomes. Cell 153, 919-929 (2013). https://doi.org/10.1016/j.cell.2013.04.010 Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and 1270 81 1271 cancer sequencing applications. *Bioinformatics* **32**, 1220-1222 (2016). https://doi.org/10.1093/bioinformatics/btv710 1272 Ding, Z. et al. Estimating telomere length from whole genome sequence data. Nucleic 1273 82 Acids Res 42, e75 (2014). https://doi.org/10.1093/nar/gku181 1274 Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. 1275 83 1276 Deciphering signatures of mutational processes operative in human cancer. Cell Rep 3, 1277 246-259 (2013). https://doi.org/10.1016/j.celrep.2012.12.008

- 1278 84 Bergstrom, E. N. *et al.* SigProfilerMatrixGenerator: a tool for visualizing and exploring
  1279 patterns of small mutational events. *BMC Genomics* 20, 685 (2019).
  1280 <u>https://doi.org/10.1186/s12864-019-6041-2</u>
- 1281 85 Diaz-Gay, M. *et al.* Assigning mutational signatures to individual samples and individual somatic mutations with SigProfilerAssignment. *Bioinformatics* 39, btad756 (2023).
  1283 https://doi.org/10.1093/bioinformatics/btad756
- 1284 86 Otlu, B. & Alexandrov, L. B. Evaluating topography of mutational signatures with
  1285 SigProfilerTopography. *bioRxiv*, 2024.2001.2008.574683 (2024).
  1286 https://doi.org/10.1101/2024.01.08.574683
- 1287 87 Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate a Practical and
  1288 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B-*1289 *Statistical Methodology* 57, 289-300 (1995). <u>https://doi.org/10.1111/j.2517-</u>
  1290 6161.1995.tb02031.x
- 1291

medRxiv preprint doi: https://doi.org/10.1101/2024.05.15.24307318; this version posted May 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Fig. 1

SBS12 SBS13 SBS17a SBS17b SBS18 SBS21 SBS22a SBS33 SBS39 SBS40a

SBS5


SBS2 SBS3 SBS4 SBS8

SBS1

SBS44

SBS92

DBS2 DBS4 DBS5 DBS6 DBS9 DBS11



DBS13

D1 **D**2 D3 ID5 ID6 D8 [D9 ID11 D14

ID19 ID24

ID23

CN1 CN2 CN6

ID10

CN18


SV10


SV7 SV9

CN7 CN9 **CN20** SV2 SV4 SV5 SV6


medRxiv preprint doi: https://doi.org/10.1101/2024.05.15.24307318; this version posted May 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Fig. 2






**G** SBS signatures assigned to driver mutations



**h** ID signatures assigned to driver mutations



medRxiv preprint doi: https://doi.org/10.1101/2024.05.15.24307318; this version posted May 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Fig. 3




Fig. 4

